[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 307
1. Aguiar Bujanda D, Aguiar Morales J, Bohn Sarmiento U, Saura Grau S, Rodríguez Franco C: Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma. Clin Transl Oncol; 2009 Sep;11(9):604-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma.
  • BACKGROUND: The results of CHOP-21 (cyclophosphamide, doxorubicin, vincristine and prednisone given every 21 days) for the treatment of aggressive B-cell lymphoma have recently been improved by the addition of rituximab and by increasing the dose density.
  • PATIENTS AND METHODS: We present our experience with R-CHOP-14 in a retrospective single-centre review of 50 patients consecutively treated for aggressive B-cell lymphoma.
  • CONCLUSIONS: In our experience the combination of RCHOP- 14 is highly effective in patients with aggressive B-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Administration Schedule. Female. Humans. Immunotherapy / methods. Male. Middle Aged. Neoplasm Invasiveness. Prednisone / administration & dosage. Prednisone / adverse effects. Radiotherapy, Adjuvant. Retrospective Studies. Rituximab. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1281-8 [6387060.001]
  • [Cites] Acta Haematol. 2006;115(1-2):22-7 [16424645.001]
  • [Cites] Hematol Oncol. 2008 Mar;26(1):27-32 [17868190.001]
  • [Cites] Leuk Lymphoma. 2005 Apr;46(4):541-7 [16019482.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] N Engl J Med. 1992 Nov 5;327(19):1342-9 [1383819.001]
  • [Cites] Haematologica. 2006 Apr;91(4):496-502 [16537117.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] Lancet Oncol. 2008 Feb;9(2):105-16 [18226581.001]
  • (PMID = 19776000.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


2. Han LN, Zhou J, Hirose T, Imai Y, Ishiguro T, Chou T: Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma. Int J Hematol; 2006 Aug;84(2):174-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma.
  • To investigate the feasibility and efficacy of high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) for patients with newly diagnosed aggressive and relapsed non-Hodgkin's lymphoma (NHL), we administered LEED, a drug-only HDCT regimen consisting of melphalan, cyclophosphamide, etoposide, and dexamethasone, followed by ASCT in this single-institution trial.
  • These results suggested that LEED, as well as R-LEED, was a safe and feasible high-dose regimen for aggressive and relapsed NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Melphalan / administration & dosage. Middle Aged. Recurrence. Rituximab. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Jul 15;102(2):749-55 [12663455.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4561-6 [15542807.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2153-64 [11304767.001]
  • [Cites] Int J Hematol. 2003 Jun;77(5):503-11 [12841390.001]
  • [Cites] Br J Haematol. 2002 Jan;116(1):229-35 [11841421.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1287-95 [15044639.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3793-801 [15809447.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Clin Lymphoma. 2005 Jun;6(1):31-6 [15989704.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):520-35 [12649096.001]
  • [Cites] Blood. 2000 Aug 1;96(3):864-9 [10910898.001]
  • [Cites] Bone Marrow Transplant. 1997 Dec;20(11):953-9 [9422474.001]
  • [Cites] N Engl J Med. 1997 May 1;336(18):1290-7 [9113932.001]
  • [Cites] Bone Marrow Transplant. 2002 May;29(9):769-75 [12040475.001]
  • [Cites] Ann Hematol. 2002;81 Suppl 2:S54-5 [12611079.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Gan To Kagaku Ryoho. 2005 Dec;32(13):2059-64 [16352929.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2472-9 [12011124.001]
  • [Cites] Blood. 2004 Feb 1;103(3):777-83 [12907446.001]
  • [Cites] Bone Marrow Transplant. 2003 Jul;32(2):139-43 [12838277.001]
  • [Cites] Haematologica. 2000 Sep;85(9):943-51 [10980633.001]
  • [Cites] Bone Marrow Transplant. 1991 Oct;8(4):239-44 [1721856.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1151-8 [12916867.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2253-9 [15512814.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2165-70 [11304768.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 1:i21-7 [12736227.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1569-73 [16236611.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1255-62 [12663712.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2240-7 [15800314.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1131-7 [9060555.001]
  • [Cites] Hematol J. 2003;4(2):110-5 [12750729.001]
  • (PMID = 16926142.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan
  •  go-up   go-down


3. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL): Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol; 2007 Jan;18(1):149-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
  • BACKGROUND: Central nervous system (CNS) relapse is a devastating and usually fatal complication of aggressive lymphoma.
  • We analyzed the patients treated on protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) between 1990 and 2000, evaluated the rate and prognostic factors for CNS recurrence and developed a risk model trying to identify subsets of patients suitable for future prophylactic strategies.
  • The protocol asked for an intrathecal (i.th.) prophylaxis in patients with lymphoblastic lymphoma only (n=17), but overall 71 patients (71 of 1693=4.2%) received prophylaxis by decision of the treating physicians.
  • Elderly patients presenting with both an elevated LDH and lymphoma involvement in liver, bladder or adrenals had an up to 15-fold risk of spread of the disease to the CNS.
  • CONCLUSION: The incidence of CNS relapse in 1693 patients treated for aggressive lymphomas on DSHNHL protocols from 1990 to 2000 was low (2.2%), although CNS prophylaxis was administered to <5% of patients.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018708.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone
  •  go-up   go-down


Advertisement
4. Clavert A, Le Gouill S, Brissot E, Dubruille V, Mahe B, Gastinne T, Blin N, Chevallier P, Guillaume T, Delaunay J, Ayari S, Saulquin B, Moreau A, Moreau P, Harousseau JL, Milpied N, Mohty M: Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma; 2010 Aug;51(8):1502-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma.
  • The role of reduced-intensity conditioning allogeneic stem cell transplant (RIC allo-SCT) in aggressive B-cell non-Hodgkin lymphoma (NHL) remains a matter of debate.
  • This single-center analysis aimed to assess the potential benefit of RIC allo-SCT in 19 consecutive patients with relapsed or transformed aggressive B-cell NHL.
  • Aggressive transformation (primary or secondary) was documented for these patients by pathological examination.
  • Overall, the incidence of non-relapse mortality was 26% (95% CI, 8-44%).
  • We conclude that RIC allo-SCT after auto-SCT is feasible and a potentially efficient therapy for relapsed or transformed aggressive B-cell NHL, warranting further prospective evaluation.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Graft vs Host Disease / prevention & control. Lymphoma, B-Cell / therapy. Neoplasm Recurrence, Local / therapy. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adult. Aged. Feasibility Studies. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Salvage Therapy. Survival Rate. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583964.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Chelly I, Mekni A, Bellil K, Belhadj Salah M, Bellil S, Haouet S, Kchir N, Horchani A, Zitouna MM: [Testicular lymphoma: report of 4 cases]. Tunis Med; 2007 Oct;85(10):896-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular lymphoma: report of 4 cases].
  • BACKGROUND: Primary testicular lymphoma is the most common testicular malignancy in the elderly, account for 1% of all non Hodgkin lymphoma (NHL).
  • The aim was to report from new cases of testicular lymphoma CASES: We report the only four cases of testicular lymphoma observed in a period of 15 years; all these cases were primary diffuse large cell B NHL.
  • Disease course is usually aggressive, with widespread organ involvement.
  • [MeSH-major] Lymphoma / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Necrosis. Neoplasm Invasiveness. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236816.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


6. Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ, Aboulafia DM, Scadden DT: Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant; 2008 Jan;14(1):59-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020.
  • Intensive chemotherapy for human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) has resulted in durable remissions in a substantial proportion of patients.
  • Based on a favorable experience with dose-reduced high-dose busulfan, cyclophosphamide, and AuSCT for older patients with non-HIV-associated aggressive lymphomas, an AIDS Malignancy Consortium multicenter trial was undertaken using the same dose-reduced busulfan and cyclophosphamide preparative regimen with AuSCT for recurrent HIV-associated NHL and HL.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18158962.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01CA070062; United States / NCI NIH HHS / CA / U01 CA070047; United States / NCI NIH HHS / CA / U01 CA070019; United States / NCI NIH HHS / CA / U01 CA083035; United States / NCI NIH HHS / CA / U01 CA083118; United States / NCI NIH HHS / CA / U01 CA071375; United States / NCI NIH HHS / CA / U01CA083216; United States / NCI NIH HHS / CA / U01CA083118; United States / NCI NIH HHS / CA / U01CA071375; United States / NCI NIH HHS / CA / U01CA070047; United States / NCI NIH HHS / CA / U01CA070054; United States / NCI NIH HHS / CA / U01 CA070054; United States / NCI NIH HHS / CA / U01CA070019; United States / NCI NIH HHS / CA / R01 CA095423; United States / NCI NIH HHS / CA / U01 CA070062; United States / NCI NIH HHS / CA / U01CA083035; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / P50 CA096888
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  • [Other-IDs] NLM/ NIHMS281894; NLM/ PMC4524737
  •  go-up   go-down


7. Murthy V, Thomas K, Foo K, Cunningham D, Johnson B, Norman A, Horwich A: Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase II study. Clin Lymphoma Myeloma; 2008 Aug;8(4):241-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase II study.
  • PURPOSE: To confirm the efficacy of low-dose involved-field radiation therapy (LD-IFRT) as palliative treatment in patients symptomatic from advanced lymphoma.
  • PATIENTS AND METHODS: A total of 36 patients (47 sites), received 4 Gy in 2 fractions to the lymphoma with a 1.5-2-cm margin.
  • Pathology subtypes included 29 (62%) sites with indolent lymphoma and 18 (36%) sites with aggressive lymphoma histology.
  • The primary endpoint of the study was in-field lymphoma control.
  • The response rate for non-diffuse large B-cell lymphoma (DLBCL) sites was 86%, while it was 50% for sites with DLBCL histology.
  • CONCLUSION: LD-IFRT is an effective and easy treatment for patients with advanced lymphoma that can be repeated at previously irradiated sites, a particularly useful attribute because of the relapsing nature, especially of advanced follicular subtypes.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Palliative Care / methods
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Patient Compliance. Quality of Life. Radiotherapy / adverse effects

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18765312.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C46/A2131
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Bolarinwa RA, Ndakotsu MA, Oyekunle AA, Salawu L, Akinola NO, Durosinmi MA: AIDS-related lymphomas in Nigeria. Braz J Infect Dis; 2009 Oct;13(5):359-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aggressive non-Hodgkin's lymphoma (NHL), including primary central nervous system (CNS) lymphoma, lymphoblastic lymphoma and non-endemic Burkitt's lymphoma have been recognized as AIDS-defining cancers in most developed countries.
  • Patients with a histological diagnosis of malignant chronic lymphoproliferative diseases {non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL), Burkitt's lymphoma (BL) and Hodgkin lymphoma (HL)} at the Obafemi Awolowo University Teaching Hospitals' Complex, Ile-Ife from January 1993 to August 2008 were noted.
  • A total of 391 patients were histologically confirmed to have lymphoma {NHL-109, (27.9%); CLL-76, (19.4%); BL-178, (45.5%) and HL-28, (7.2%)} during the study period.
  • However, it is interesting that no single case of AIDS-associated BL was seen, despite the fact that Burkitt's lymphoma is endemic in this part of the world.
  • [MeSH-major] Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Adult. Female. Humans. Incidence. Male. Middle Aged. Nigeria / epidemiology. Prevalence. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428636.001).
  • [ISSN] 1678-4391
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


9. Deleeuw RJ, Zettl A, Klinker E, Haralambieva E, Trottier M, Chari R, Ge Y, Gascoyne RD, Chott A, Müller-Hermelink HK, Lam WL: Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology; 2007 May;132(5):1902-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes.
  • BACKGROUND & AIMS: Enteropathy-type T-cell lymphoma (ETL) is an aggressive extranodal T-cell non-Hodgkin lymphoma assumed to arise in the setting of celiac disease.
  • CONCLUSIONS: Contrary to current clinical classification, ETL comprises 2 morphologically, clinically, and genetically distinct lymphoma entities.
  • [MeSH-major] Celiac Disease / genetics. Genome, Human / genetics. HLA-DQ Antigens / genetics. Lymphoma, T-Cell / classification. Lymphoma, T-Cell / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD56 / genetics. Antigens, CD56 / metabolism. Antigens, CD8 / genetics. Antigens, CD8 / metabolism. Chromosome Mapping. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 5 / genetics. DNA, Neoplasm / genetics. Female. Gene Expression Regulation, Neoplastic. Genotype. HLA-DQ beta-Chains. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484883.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Antigens, CD8; 0 / DNA, Neoplasm; 0 / HLA-DQ Antigens; 0 / HLA-DQ beta-Chains; 0 / HLA-DQ2 antigen; 0 / HLA-DQ8 antigen; 0 / HLA-DQB1 antigen
  •  go-up   go-down


10. Bodet-Milin C, Kraeber-Bodéré F, Moreau P, Campion L, Dupas B, Le Gouill S: Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica; 2008 Mar;93(3):471-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma.
  • Positron emission tomography using 18F-fluorodeoxyglucose (FDG-PET) has been successfully evaluated in the management of non-Hodgkin's lymphoma (NHL).1-3 Histological transformation (HT) of indolent lymphoma is a dramatic event that occurs in 5-10% of the patients and carries a dismal prognosis.4,5 Previous studies prove that indolent lymphoma entities show a lower FDG uptake when compared with aggressive lymphomas.6-8 We therefore postulated that FDG-PET/CT identifies aggressive transformation sites and can guide biopsies.
  • [MeSH-major] Biopsy / methods. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography. Radiology, Interventional / methods. Radiopharmaceuticals. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Disease Progression. Female. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18310543.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


11. Zhai L, Guo C, Cao Y, Xiao J, Fu X, Huang J, Huang H, Guan Z, Lin T: Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience. Int J Hematol; 2010 Jan;91(1):78-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience.
  • Few studies have compared the long-term outcomes of patients receiving pirarubicin-based THP-COP and doxorubicin-based CHOP in the treatment of non-Hodgkin's lymphoma (NHL).
  • We retrospectively compared the efficacy and safety of these two regimens in 459 previously untreated aggressive NHL patients admitted to Sun Yat-Sen University Cancer Center from 1987 to 2003.
  • At a median follow-up of 95.7 months, the 8-year survival rates were also similar (overall survival: THP-COP, 55.8% vs. CHOP, 56.7%; progression-free survival: THP-COP, 47.3% vs. CHOP, 43.5%; lymphoma-specific survival: THP-COP, 51.2% vs. CHOP, 48.5%).
  • In combination chemotherapy for aggressive NHL, pirarubicin has comparable efficacy to doxorubicin and has a lower incidence of alopecia, gastrointestinal toxicities, and arrhythmia.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Doxorubicin / analogs & derivatives. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cancer Res Clin Oncol. 2004 Feb;130(2):107-13 [14648210.001]
  • [Cites] Int J Mol Med. 1998 Feb;1(2):491-4 [9852255.001]
  • [Cites] Hematol Oncol. 2007 Sep;25(3):107-14 [17457949.001]
  • [Cites] Int J Hematol. 2005 Apr;81(3):246-54 [15814336.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Ann Intern Med. 1979 Nov;91(5):710-7 [496103.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2007 May;29(5):391-5 [17892140.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):602-11 [11157009.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;23(5):311-5 [2706737.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Eur J Cancer. 1992;28A(10):1670-6 [1389483.001]
  • [Cites] Gan To Kagaku Ryoho. 1997 Jan;24(1):61-6 [9020947.001]
  • [Cites] J Antibiot (Tokyo). 1979 Oct;32(10):1082-4 [528373.001]
  • [Cites] Leukemia. 1997 Nov;11(11):1817-20 [9369412.001]
  • [Cites] Pediatr Res. 2002 Feb;51(2):256-9 [11809923.001]
  • [Cites] Gan To Kagaku Ryoho. 1984 Jan;11(1):138-42 [6696455.001]
  • [Cites] J Antibiot (Tokyo). 1979 Oct;32(10):1085-6 [528374.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Oncology. 1990;47(1):25-8 [2300381.001]
  • [Cites] Hematol J. 2000;1(1):53-66 [11920170.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2311-20 [9404709.001]
  • [Cites] Tsitologiia. 1997;39(10):928-37 [9505340.001]
  • [Cites] Rinsho Ketsueki. 1993 Dec;34(12):1532-9 [8295326.001]
  • [Cites] Ann Oncol. 1992 May;3(5):379-86 [1616892.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):847-52 [15465202.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2005 Oct;26(10):577-80 [16532963.001]
  • [Cites] Biomed Pharmacother. 1986;40(10):376-9 [3580506.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Ann Oncol. 1996 Nov;7(9):966-9 [9006749.001]
  • [Cites] Am J Clin Oncol. 1990;13 Suppl 1:S15-9 [2291455.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] Radiat Med. 2005 May;23(3):156-61 [15940061.001]
  • (PMID = 20033628.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; D58G680W0G / pirarubicin; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


12. Oyama T, Yamamoto K, Asano N, Oshiro A, Suzuki R, Kagami Y, Morishima Y, Takeuchi K, Izumo T, Mori S, Ohshima K, Suzumiya J, Nakamura N, Abe M, Ichimura K, Sato Y, Yoshino T, Naoe T, Shimoyama Y, Kamiya Y, Kinoshita T, Nakamura S: Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res; 2007 Sep 1;13(17):5124-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Patients with age-related EBV+ B-cell LPDs showed a higher age distribution and aggressive clinical features or parameters than EBV-negative DLBCLs: 44% with performance status >1, 58% with serum lactate dehydrogenase level higher than normal, 49% with B symptoms, and higher involvement of skin and lung.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. CD4-Positive T-Lymphocytes / immunology. Female. Hodgkin Disease / pathology. Humans. Immunophenotyping. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785567.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Muslimani AA, Farag HL, Francis S, Spiro TP, Chaudhry AA, Chan VC, Taylor HC, Daw HA: The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma. Am J Clin Oncol; 2008 Oct;31(5):409-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma.
  • PURPOSE: In non-Hodgkin lymphomas (NHLs), the bone marrow (BM) involvement is a sign of extensive disease and the iliac crest BM biopsy (BMB) is the established method for the detection of BM infiltration.
  • Further analysis revealed no significant difference in the ability of the F-FDG PET scan to detect BM involvement between the indolent-NHL and the aggressive/highly aggressive-NHL groups (sensitivity P = 0.23, specificity P = 0.64).
  • [MeSH-major] Bone Marrow / radionuclide imaging. Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography / utilization. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838874.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


14. Mohile NA, Deangelis LM, Abrey LE: Utility of brain FDG-PET in primary CNS lymphoma. Clin Adv Hematol Oncol; 2008 Nov;6(11):818-20, 840
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of brain FDG-PET in primary CNS lymphoma.
  • 18Fluoro-deoxyglucose positron emission tomography (FDG-PET) imaging has been widely incorporated into the management of systemic non-Hodgkin lymphoma.
  • However, its utility in primary central nervous system lymphoma (PCNSL) is unclear.
  • Baseline PET imaging demonstrated hypermetabolism consistent with aggressive lymphoma in 75% (9/12) of patients.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Lymphoma / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain / pathology. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194366.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


15. Ali AE, Morgen EK, Geddie WR, Boerner SL, Massey C, Bailey DJ, da Cunha Santos G: Classifying B-cell non-Hodgkin lymphoma by using MIB-1 proliferative index in fine-needle aspirates. Cancer Cytopathol; 2010 Jun 25;118(3):166-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classifying B-cell non-Hodgkin lymphoma by using MIB-1 proliferative index in fine-needle aspirates.
  • BACKGROUND: MIB-1 proliferation index (PI) has proven helpful for diagnosis and prognosis in non-Hodgkin lymphomas (NHLs).
  • Cases were subtyped according to the current World Health Organization classification and separated into indolent, aggressive, and highly aggressive groups.
  • RESULTS: Ninety-one NHL cases were subdivided in 56 (61.5%) indolent, 30 (33%) aggressive, and 5 (5.5%) highly aggressive lymphomas.
  • Cutpoints were established for separating indolent (<38%), aggressive (> or =38% to < or =80.1%) and highly aggressive (>80.1%).
  • Discrepant MIB-1 PIs were related to dilution of positive cells by non-neoplastic lymphocytes and to the overlapping continuum of features between diffuse large B-cell lymphoma and Burkitt lymphoma.
  • [MeSH-major] Antibodies, Antinuclear / analysis. Antibodies, Monoclonal / analysis. Biopsy, Fine-Needle. Lymphoma, B-Cell / classification
  • [MeSH-minor] Adult. Aged. Cell Proliferation. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Middle Aged


16. Welt A, Schütt P, Derks C, Ebeling P, Müller S, Metz K, Anhuf J, Moritz T, Seeber S, Nowrousian MR: Long-term results of a phase-I/II study of sequential high-dose chemotherapy with autologous stem cell transplantation in the initial treatment of aggressive non-Hodgkin's lymphoma. Tumori; 2007 Sep-Oct;93(5):409-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of a phase-I/II study of sequential high-dose chemotherapy with autologous stem cell transplantation in the initial treatment of aggressive non-Hodgkin's lymphoma.
  • AIMS AND BACKGROUND: To improve the survival of patients with aggressive non-Hodgkin's lymphoma, we evaluated a risk-adapted therapeutic approach using high-dose (HD) or conventional-dose (CD) chemotherapy (CT) for poor-risk and good-risk patients, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Carboplatin / administration & dosage. Combined Modality Therapy. Dexamethasone / administration & dosage. Etoposide / administration & dosage. Feasibility Studies. Female. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Remission Induction. Survival Rate. Transplantation, Autologous. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038870.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


17. Soliman KB, Abbas MM, Seksaka MA, Wafa S, Balah AS: Aggressive primary thyroid non Hodgkin's lymphoma with pregnancy. Saudi Med J; 2007 Apr;28(4):634-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive primary thyroid non Hodgkin's lymphoma with pregnancy.
  • She was diagnosed as an aggressive non-Hodgkin lymphoma of the thyroid gland.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Pregnancy Complications, Neoplastic. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Prednisone / therapeutic use. Pregnancy. Pregnancy Outcome. Vincristine / therapeutic use


18. Elbl L, Vasova I, Tomaskova I, Jedlicka F, Navratil M, Pospisil Z, Vorlicek J: Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma. Neoplasma; 2006;53(2):174-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma.
  • Authors conducted a one-year prospective study to determine whether CHOP regimen (cyclophosphamide, doxorubicin, vincristin, and prednisone), used in the treatment of aggressive non-Hodgkin s lymphoma, is associated with the presence of an early impairment of cardiac function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Heart / drug effects. Lung / drug effects. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Cyclophosphamide / adverse effects. Dose-Response Relationship, Drug. Doxorubicin / adverse effects. Echocardiography. Exercise Test / drug effects. Female. Heart Function Tests. Humans. Male. Middle Aged. Prednisone / adverse effects. Prospective Studies. Respiratory Function Tests. Sex Factors. Ventricular Function, Left / drug effects. Vincristine / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575475.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


19. Niu Y, Shi Y, Zhou S, Pan F, Wu S, Liu P, Yang J, Han X, He X: Study of conditioning regimens with or without high-dose radiotherapy before autologous stem cell transplantation for treating aggressive lymphoma. Int J Hematol; 2009 Jan;89(1):106-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of conditioning regimens with or without high-dose radiotherapy before autologous stem cell transplantation for treating aggressive lymphoma.
  • The aim and objective of the study is to compare the efficacy of conditioning regimens with or without high-dose radiotherapy for treating aggressive non-Hodgkin's lymphoma (NHL).
  • Eighty-nine aggressive NHL patients who underwent high-dose therapy in combination with autologous stem cell transplantation (HDT/ASCT) between 1993 and 2006 were retrospectively studied.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Radiotherapy. Radiotherapy Dosage. Retrospective Studies. Transplantation, Autologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2000 Aug;26(3):321-6 [10967573.001]
  • [Cites] Cancer Treat Rev. 2007 Jun;33(4):338-46 [17400393.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3562-8 [9808548.001]
  • [Cites] J Natl Cancer Inst. 2001 Jan 3;93(1):22-30 [11136838.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1504-9 [15367411.001]
  • [Cites] Blood. 1996 May 1;87(9):3633-9 [8611687.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1287-95 [15044639.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2399-404 [11001890.001]
  • [Cites] Zhonghua Nei Ke Za Zhi. 2002 Jun;41(6):363-6 [12137594.001]
  • [Cites] Blood. 2003 Sep 15;102(6):1989-96 [12676776.001]
  • [Cites] Oncologist. 1999;4(5):386-97 [10551555.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):48-55 [9440722.001]
  • [Cites] N Engl J Med. 1995 Apr 20;332(16):1045-51 [7898521.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):406-13 [11208832.001]
  • [Cites] Blood. 1976 May;47(5):747-56 [769864.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2003 Nov;25(6):592-5 [14690571.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):332-9 [10637247.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2208-14 [15753460.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):897-906 [12610191.001]
  • [Cites] Blood. 1998 May 1;91(9):3148-55 [9558369.001]
  • (PMID = 19067117.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Aboud A, Marx G, Sayer H, Gummert JF: Successful treatment of an aggressive non-Hodgkin's lymphoma associated with acute respiratory insufficiency using extracorporeal membrane oxygenation. Interact Cardiovasc Thorac Surg; 2008 Feb;7(1):173-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of an aggressive non-Hodgkin's lymphoma associated with acute respiratory insufficiency using extracorporeal membrane oxygenation.
  • Non-Hodgkin's lymphoma initially presenting as a solid huge mediastinal mass does not frequently occur.
  • Although nowadays many patients with high-grade (aggressive) malignant lymphoma can be cured using a combination of immuno- and chemotherapy, rapid progression and acute complications caused by the tumor mass itself may necessitate additional invasive treatment.
  • We report a case of successful extracorporeal membrane oxygenation treatment in a 43-year-old woman with acute respiratory insufficiency due to a huge mediastinal non-Hodgkin's tumor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Extracorporeal Membrane Oxygenation / methods. Immunosuppressive Agents / therapeutic use. Lymphoma, Non-Hodgkin / therapy. Mediastinal Neoplasms / therapy. Respiratory Insufficiency / therapy
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Respiratory Function Tests

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18045830.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


21. Paydas S, Ergin M, Erdogan S, Seydaoglu G, Yavuz S, Disel U: Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas. Leuk Res; 2008 Feb;32(2):243-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas.
  • Survivin (S) is a member of inhibitor of apoptosis family (IAP) and is expressed in the majority of malignant tumors but undetectable in normal differentiated adult tissues.
  • We aimed to determine the pathogenetic and prognostic role of TSP-1 and S in non-Hodgkin's lymphomas (NHL).
  • There was a strong association between S and TSP-1 and also aggressive histology with S and TSP-1.
  • In conclusion, S and TSP-1 expressions were detected in 53 and 17.5% of the cases with NHL, and are associated with aggressive histology and shorter OS.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lymphoma, Non-Hodgkin / metabolism. Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis. Thrombospondin 1 / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706282.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Thrombospondin 1
  •  go-up   go-down


22. Vladareanu AM, Ciufu C, Neagu AM, Onisai M, Bumbea H, Vintilescu AM, Dobrea C, Arama V, Mihailescu R, Arama S: The impact of hepatitis viruses on chronic lymphoproliferative disorders--preliminary results. J Med Life; 2010 Jul-Sep;3(3):320-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological types of CLD: B-cell non-Hodgkin's lymphoma--in 28/41 (68.29%) patients, T-cell non-Hodgkin's lymphoma--2/41 (4.87%) patients, Hodgkin's lymphoma--2/41 (4.87%), chronic lymphocytic leukemia--7/41 (17.07%), Waldenström disease--2/41 (4.87%) patients.
  • Regarding the type of CLD, 19/41 (46.34%) of the patients have an aggressive type of CLD and 22/41 (53.65%) a non-aggressive type of CLD.
  • Within HBV infection subgroup 9/14 (64.28%) patients have an aggressive type of CLD and 5/14 (35,71%) patients have a non-aggressive type, whereas within the group with HCV infection we found a different distribution: 9/24 (37,5%) patients with aggressive type and 15/24 (62.5%) with non-aggressive type of CLD.
  • The clinical parameters monitored were: B signs were present in 19/41 (43.34%) patients, the superficial or profound adenopathies--were found in 29/41 (70,73%) patients, hepatomegaly--in 38/41 (92,68%) patients, splenomegaly--in 21/41 (51.21%) patients, extra-nodal involvements in 10/41 (24,39%) patients and most frequent in the non-aggressive type of CLD--6/10 (60%) patients.
  • The hematological and biochemical parameters were: the presence of anemia and thrombocytopenia--found in a small number of patients; lymphocytosis--positive in 33/41 (80.48%) patients, most with HCV infection and non-aggressive type of disease, the presence of autoimmune hemolytic anemia--in 4/41 (9.75%) patients, cryoglobulins--8/41 (19.51%) patients, all with HCV infection; also the liver function was monitored.
  • A strong association between B-cell chronic lymphoproliferative disorders and hepatitis viral infection B, C, D was revealed, the most frequent being the C hepatitis virus, associated with the non-aggressive type of CLD, extra-nodal involvement, splenomegaly, lymphocytosis, cryoglobulins, cytolysis and colestasis.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatitis B, Chronic / complications. Hepatitis C, Chronic / complications. Hepatitis D, Chronic / complications. Humans. Lymphoma, Non-Hodgkin / etiology. Male. Middle Aged. Prospective Studies. Retrospective Studies. Romania

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1999 Dec;10(12):1419-32 [10643532.001]
  • [Cites] Curr Oncol Rep. 2000 Mar;2(2):172-5 [11122840.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3745-9 [11739181.001]
  • [Cites] Am J Gastroenterol. 2002 Jul;97(7):1802-6 [12135039.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Br J Haematol. 1994 Oct;88(2):392-4 [7803287.001]
  • [Cites] Ann Intern Med. 1996 Jan 1;124(1 Pt 1):31-4 [7503475.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Blood. 1997 Jul 15;90(2):776-82 [9226178.001]
  • [Cites] Leuk Lymphoma. 1997 Jun;26(1-2):127-30 [9250797.001]
  • [Cites] J Hepatol. 1998 Jan;28(1):34-9 [9537861.001]
  • [Cites] Am J Clin Pathol. 1998 May;109(5):600-9 [9576580.001]
  • [Cites] Clin Lab Haematol. 1998 Apr;20(2):107-10 [9681221.001]
  • [Cites] Blood. 2005 Jan 1;105(1):74-6 [15353484.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:375-80 [17124086.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):346-50 [17071937.001]
  • (PMID = 20945824.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Other-IDs] NLM/ PMC3019001
  •  go-up   go-down


23. Park SH, Kim S, Ko OB, Koo JE, Lee D, Jeong YP, Huh J, Kim SB, Kim SW, Lee JL, Suh C: ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience. Korean J Intern Med; 2006 Sep;21(3):159-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience.
  • BACKGROUND: The ESHAP chemotherapy regimen, that is, the combination of the etoposide, methylprednisolone, high-dose cytarabine and cisplatin, has been shown to be active against relapsing or refractory non-Hodgkin's lymphoma (NHL) in previous therapeutic trials.
  • METHODS: Twenty two patients with refractory or relapsed NHLs (all aggressive types) were enrolled in this study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Disease Progression. Etoposide / administration & dosage. Female. Humans. Male. Methylprednisolone / administration & dosage. Middle Aged. Prednisone. Survival Analysis. Treatment Failure

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):12-20 [10561013.001]
  • [Cites] Jpn J Clin Oncol. 1999 Jan;29(1):33-7 [10073149.001]
  • [Cites] Semin Oncol. 2004 Feb;31(1 Suppl 2):12-6 [15042529.001]
  • [Cites] Blood. 1978 Jul;52(1):85-95 [350316.001]
  • [Cites] Cancer Res. 1981 Jan;41(1):25-30 [7192598.001]
  • [Cites] Blood. 1982 Sep;60(3):693-7 [7104493.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):407-12 [3819806.001]
  • [Cites] N Engl J Med. 1987 Jun 11;316(24):1493-8 [3295541.001]
  • [Cites] Semin Hematol. 1987 Apr;24(2 Suppl 1):21-5 [2438778.001]
  • [Cites] Blood. 1988 Jan;71(1):117-22 [3334893.001]
  • [Cites] Cancer. 1989 Oct 1;64(7):1388-92 [2776103.001]
  • [Cites] Ann Oncol. 1991 Jan;2 Suppl 1:31-2 [1904269.001]
  • [Cites] Ann Oncol. 1991 Jun;2(6):431-5 [1722697.001]
  • [Cites] Ann Oncol. 1993 Jan;4(1):63-7 [8435365.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1023-30 [8450856.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1573-82 [7687667.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1169-76 [8201379.001]
  • [Cites] Ann Oncol. 1994 May;5(5):453-6 [8075052.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1734-41 [7602363.001]
  • [Cites] Hematol Oncol Clin North Am. 1997 Oct;11(5):937-47 [9336723.001]
  • [Cites] J Korean Med Sci. 2002 Oct;17(5):621-4 [12378012.001]
  • (PMID = 17017664.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; X4W7ZR7023 / Methylprednisolone; ESHAP regimen
  • [Other-IDs] NLM/ PMC3890718
  •  go-up   go-down


24. Balogun TM, Omodele FO, Olaiya MA: Primary lymphoma of the testis in remission for more than ten years: a case report. West Afr J Med; 2009 Nov-Dec;28(6):388-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the testis in remission for more than ten years: a case report.
  • BACKGROUND: Primary testicular lymphoma is a unique, rare and aggressive extra nodal non-Hodgkins Lymphoma (NHL).
  • It is the most common testicular tumour in males between 60 and 80 years old OBJECTIVE: To report a case of primary testicular lymphoma in a young man who has done very well on surgery and chemotherapy.
  • CONCLUSION: Primary testicular lymphoma is a rare and unique neoplasm of the testis and is most commonly seen in men over the age of 60, but should be considered in the differential diagnosis of testicular tumours in younger age groups.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Testicular Diseases / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Humans. Male. Orchiectomy. Remission Induction. Spermatic Cord / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20486099.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


25. Gorschlüter M, Mey U, Strehl J, Schepke M, Lamberti C, Sauerbruch T, Glasmacher A: Cholecystitis in neutropenic patients: retrospective study and systematic review. Leuk Res; 2006 May;30(5):521-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We calculated a frequency of 0.4% among all neutropenic episodes in patients with acute leukemia or aggressive lymphoma undergoing myelosuppressive chemotherapy.
  • [MeSH-major] Cholecystitis / etiology. Leukemia / therapy. Lymphoma, Non-Hodgkin / therapy. Neutropenia / complications
  • [MeSH-minor] Acute Disease. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Cholecystitis.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16483649.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 41
  •  go-up   go-down


26. Akoum R, Brihi E, Saade M, Hanna T, Chahine G: Salvage abdominal irradiation for refractory non-Hodgkin's lymphoma. J Cancer Res Ther; 2007 Jul-Sep;3(3):143-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominal irradiation for refractory non-Hodgkin's lymphoma.
  • BACKGROUND: Abdominal irradiation, as a part of treatment, is often ignored in the management of refractory non-Hodgkin's lymphoma (NHL).
  • MATERIALS AND METHODS: 27 patients with intraabdominal lymphoma underwent salvage irradiation between 1982 and 2001.
  • Thirteen patients, six with follicular and seven with aggressive tumors, had refractory relapsed tumors after achieving one or more complete remissions.
  • Survival rates were significantly better for patients with refractory relapse compared to those with primary refractory lymphoma (P < 0.01).
  • There was no significant difference in terms of response, recurrence, or survival rates between follicular and aggressive types.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Salvage Therapy
  • [MeSH-minor] Abdomen. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079576.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


27. Pelosi E, Pregno P, Penna D, Deandreis D, Chiappella A, Limerutti G, Vitolo U, Mancini M, Bisi G, Gallo E: Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Radiol Med; 2008 Jun;113(4):578-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
  • PURPOSE: The aim of this study was to evaluate the role of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in the staging of Hodgkin's and aggressive non-Hodgkin's lymphoma (HL and NHL), comparing it with conventional diagnostic methods, i.e. contrast-enhanced CT and bone marrow biopsy.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / diagnostic imaging. Lymphoma, Non-Hodgkin / diagnostic imaging. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Sensitivity and Specificity


28. Giuliante F, Sarno G, Ardito F, Pierconti F: Primary hepatic leiomyosarcoma in a young man after Hodgkin's disease: diagnostic pitfalls and therapeutic challenge. Tumori; 2009 May-Jun;95(3):374-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic leiomyosarcoma in a young man after Hodgkin's disease: diagnostic pitfalls and therapeutic challenge.
  • PATIENT CASE: A 26-year-old male patient with a previous history of radiochemotherapy treatment for Hodgkin's lymphoma was referred to our unit with a histological and radiological diagnosis of primary hepatic leiomyosarcoma.
  • CONCLUSIONS: The challenges and peculiarities of this case are related to the rarity of the tumor, its accidental discovery without immediate suspicion of its nature, its very aggressive behavior that was only partly controlled by chemotherapy, and the unusual expression of a neuroendocrine phenotypic feature with high serum chromogranin A levels.
  • [MeSH-major] Hodgkin Disease. Leiomyosarcoma. Liver Neoplasms. Neoplasms, Second Primary
  • [MeSH-minor] Adult. Fatal Outcome. Hepatectomy. Humans. Male. Tomography, X-Ray Computed


29. Sattar T, Griffeth LK, Latifi HR, Glass J, Munker R, Lilien DL: PET imaging today: contribution to the initial staging and prognosis of patients with non-Hodgkin's lymphomas. J La State Med Soc; 2006 Jul-Aug;158(4):193-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET imaging today: contribution to the initial staging and prognosis of patients with non-Hodgkin's lymphomas.
  • Malignant non-Hodgkin lymphomas (NHLs) are commonly staged according to the Ann Arbor staging system developed for Hodgkin's lymphoma.
  • In the subtype of high grade NHL diffuse large B cell lymphoma, upstaging by PET appears to be clinically relevant as a marker for a more aggressive tumor.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fluorodeoxyglucose F18. Humans. Male. Medical Audit. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17022364.001).
  • [ISSN] 0024-6921
  • [Journal-full-title] The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society
  • [ISO-abbreviation] J La State Med Soc
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


30. Liu XM, Wang HQ, Zhang HL, Qiu LH, Li W, Li LF, Cui XZ, Liu PF, Hao XS: [DNCE regimen for treatment of refractory or relapsed aggressive and highly aggressive non-Hodgkin lymphoma]. Zhonghua Zhong Liu Za Zhi; 2008 Oct;30(10):779-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [DNCE regimen for treatment of refractory or relapsed aggressive and highly aggressive non-Hodgkin lymphoma].
  • OBJECTIVE: To evaluate the efficacy and safety of DNCE [DXM, navelbine (NVB), DDP and Vp-16] regimen and DICE [dexamethasone (DXM), ifosfamide (IFO), cisplatin (DDP) and etoposide (Vp-16)] regimen in the treatment of refractory or relapsed aggressive and highly aggressive non-Hodgkin lymphoma (NHL).
  • METHODS: A total of 69 patients with histopathologically proved advanced aggressive and highly aggressive NHL were randomized into trial group (32 patients treated with DNCE regimen) and control group (37 patients treated with DICE regimen).
  • RESULTS: A better efficacy was shown in the complete response rate, partial response rate, and total response rate between DNCE and DICE groups (18.8% vs. 10.8%, 37.5% vs. 35.1%, and 56.3% vs. 45.9%, respectively), but the differences were statistically non-significant (P > 0.05).
  • Therefore, the DNCE regimen is an effective second-line salvage regimen for the treatment of refractory or relapsed aggressive and highly aggressive non-Hodgkin lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / therapeutic use. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Etoposide / administration & dosage. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Ifosfamide / adverse effects. Ifosfamide / therapeutic use. Leukopenia / chemically induced. Male. Middle Aged. Nausea / chemically induced. Neoplasm Recurrence, Local. Neoplasm Staging. Remission Induction. Survival Rate. Thrombocytopenia / chemically induced. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173813.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine; UM20QQM95Y / Ifosfamide; DICE protocol
  •  go-up   go-down


31. van Imhoff GW, van der Holt B, Mackenzie MA, Van't Veer MB, Wijermans PW, Ossenkoppele GJ, Schouten HC, Sonneveld P, Steijaert MM, Kluin PM, Kluin-Nelemans HC, Verdonck LF, Dutch-Belgian Hemato-Oncology Cooperative Group: Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. J Clin Oncol; 2005 Jun 1;23(16):3793-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
  • PURPOSE: Timing, appropriate amount, and composition of treatment before high-dose therapy and autologous stem-cell transplantation (ASCT) in patients with poor-risk, aggressive non-Hodgkin's lymphoma (NHL) are still unknown.
  • We conducted two consecutive multicenter phase II trials with up-front, high-dose, sequential chemotherapy and ASCT in poor-risk, aggressive NHL.
  • PATIENTS AND METHODS: Between 1994 and 2001, 147 newly diagnosed, poor-risk, aggressive NHL patients, age < or = 65 years with stage III to IV and lactate dehydrogenase (LDH) more than 1.5x upper limit of normal (ULN), entered the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) -27 and HOVON-40 trials.
  • RESULTS: Patient characteristics in both trials were comparable: 80% had diffuse large B-cell lymphoma, 77% had stage IV disease, and median LDH levels were 3.1x ULN.
  • CONCLUSION: In patients with poor-risk, aggressive NHL, addition of intensified CHOP before up-front, high-dose, sequential therapy and ASCT significantly improved the duration of response and survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisone / administration & dosage. Prognosis. Remission Induction. Risk Factors. Stem Cell Transplantation. Survival Rate. Transplantation, Autologous. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15809447.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


32. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM: Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol; 2008 Oct 20;26(30):4952-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
  • PURPOSE: The major cause of death in aggressive lymphoma is relapse or nonresponse to initial therapy.
  • Lenalidomide has activity in a variety of hematologic malignancies, including non-Hodgkin's lymphoma (NHL).
  • We report the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of lenalidomide oral monotherapy in patients with relapsed or refractory aggressive NHL.
  • The most common histology was diffuse large B-cell lymphoma (53%), and patients had received a median of four prior treatment regimens for NHL.
  • Responses were observed in each aggressive histologic subtype tested (diffuse large B-cell, follicular center grade 3, mantle cell, and transformed lymphomas).
  • CONCLUSION: Oral lenalidomide monotherapy is active in relapsed or refractory aggressive NHL, with manageable side effects.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Recurrence, Local / drug therapy. Thalidomide / analogs & derivatives
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Hematologic Diseases / chemically induced. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Male. Middle Aged. Prospective Studies. Remission Induction


33. Ambrosini V, Rubello D, Castellucci P, Nanni C, Farsad M, Zinzani P, Alavi A, Tehranipour N, Al-Nahhas A, Fanti S: Diagnostic role of 18F-FDG PET in gastric MALT lymphoma. Nucl Med Rev Cent East Eur; 2006;9(1):37-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic role of 18F-FDG PET in gastric MALT lymphoma.
  • BACKGROUND: The aim of the study was to evaluate the usefulness of 18F-FDG-PET in patients with gastric lymphoma, in particular those affected by mucosa-associated lymphoid tissue (MALT) type and aggressive gastric non-Hodgkin's lymphoma (NHL).
  • In 9/15 patients the subsequent histological evaluation was consistent with a gastric MALT lymphoma, while aggressive gastric NHL was diagnosed in the other 6/15.
  • RESULTS: Overall 18F-FDG-PET was true positive in all cases of gastric MALT and non-MALT aggressive NHL with known active disease, while no pathological 18F-FDG uptake was evident in the subjects who were in complete clinical remission.
  • The degree of 18F-FDG uptake (mean SUVmax values) in MALT lymphoma was much less intense in comparison to aggressive gastric NHL, suggesting a prognostic role of SUV calculation in gastric lymphomas.
  • CONCLUSION: Our data demonstrate the significant accuracy of 18F-FDG-PET in detecting active disease in gastric lymphoma of both MALT and non-MALT NHL type.
  • A higher SUV value appears to be related to a more aggressive disease.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / radionuclide imaging. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography / methods. Stomach Neoplasms / diagnosis. Stomach Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphoma. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791802.001).
  • [ISSN] 1506-9680
  • [Journal-full-title] Nuclear medicine review. Central & Eastern Europe
  • [ISO-abbreviation] Nucl Med Rev Cent East Eur
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


34. Yang DH, Min JJ, Jeong YY, Ahn JS, Kim YK, Cho SH, Chung IJ, Bom HS, Kim HJ, Lee JJ: The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma. Ann Hematol; 2009 May;88(5):425-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
  • We investigated the concomitant interim response of patients with aggressive non-Hodgkin's lymphoma (NHL) using multi-detector row computerized tomography (CT) and (18)F-fluoro-2-deoxy-D: -glucose-positron emission tomography (PET)/CT for prediction of clinical outcomes.
  • One hundred six newly diagnosed patients with aggressive NHL were enrolled.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Neoplasm, Residual / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Fluorodeoxyglucose F18. Humans. Male. Metabolism. Middle Aged. Prognosis. Remission Induction. Survival Analysis. T-Lymphocytes. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19002686.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


35. Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, Loren A, Phillips J, Nasta S, Perl A, Schuster S, Tsai D, Sohal A, Veloso E, Emerson S, June CH: A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood; 2006 Feb 15;107(4):1325-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with aggressive malignancies received induction chemotherapy, and all patients received conventional DLI (median, 1.5 x 10(8) mononuclear cells/kg) followed 12 days later by aDLI.
  • Eight patients achieved complete remission, including 4 of 7 with acute lymphocytic leukemia (ALL), 2 of 4 with acute myelogenous leukemia (AML), 1 with chronic lymphocytic leukemia (CLL), and 1 of 2 with non-Hodgkin lymphoma (NHL).
  • [MeSH-major] Antigens, CD28 / blood. Antigens, CD8 / blood. Leukemia / therapy. Lymphocyte Transfusion / adverse effects. Lymphoma / therapy. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Adolescent. Adult. Antigens, CD / blood. Child. Female. Humans. Lymphocyte Activation. Male. Middle Aged. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269610.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD28; 0 / Antigens, CD8
  •  go-up   go-down


36. Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, Mapara M, Dörken B, Ko Y, Metzner B, Kisro J, Diehl V, Engert A: High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol; 2005 Aug;16(8):1359-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
  • BACKGROUND: Combination chemotherapy can cure patients with non-Hodgkin's lymphoma (NHL), but those who suffer treatment failure or relapse still have a poor prognosis.
  • PATIENTS AND METHODS: Inclusion criteria were age 18-65 years, histologically proven primary progressive or relapsed aggressive NHL and eligibility for HDCT.
  • This program is currently being modified by addition of rituximab for patients with relapsed aggressive NHL.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15939712.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine
  •  go-up   go-down


37. Todeschini G, Tecchio C, Pasini F, Benedetti F, Cantini M, Crippa C, Draisci M, Pizzolo G: Hyperfractionated cyclophosphamide with high-doses of arabinosylcytosine and methotrexate (HyperCHiDAM Verona 897). Cancer; 2005 Aug 1;104(3):555-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Patients who have aggressive, refractory or recurrent non-Hodgkin lymphomas (NHLs) that are refractory to first-line anthracycline-containing regimens (ACRs) have a dismal outcome.
  • METHODS: Between February 1998 and May 2002, 28 consecutive adult patients (median age, 44 years) with aggressive NHL (B-lineage in 21%, T-lineage in 7%, and Ki-67 percentage > 50 in 82%) were entered on the protocol after they had failed on ACRs (15 patients with refractory disease, 6 patients with stable disease, 5 patients with recurrent disease, and 2 patients in partial remission).
  • CONCLUSIONS: HyperCHiDAM Verona 897 was an effective regimen for patients with aggressive NHL who failed on ACRs, and it allowed patients to undergo subsequent SCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / therapy. Salvage Therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Anthracyclines / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / therapy. Male. Methotrexate / administration & dosage. Middle Aged. Prognosis. Remission Induction. Survival Rate. Transplantation, Autologous. Treatment Outcome

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15959910.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


38. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI: Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma; 2005 Nov;46(11):1569-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
  • The present study aimed to determine the long-term safety and efficacy of chimeric anti-CD 20 antibody rituxan (rituximab, Biogen IDEC, San Diego, CA, USA; Genentech, South San Francisco, CA, USA) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy in previously untreated patients with aggressive non-Hodgkin's lymphoma (NHL).
  • Thirty-three patients with previously untreated aggressive B-cell NHL received six infusions of rituximab (375 mg/m(2) per dose) on day 1 of each cycle of CHOP chemotherapy, given on day 3 of each cycle of therapy.
  • The long-term follow-up of patients in this phase II trial of rituximab with CHOP chemotherapy for previously untreated aggressive NHL demonstrates a high response rate, which remains very durable with high 5-year overall and progression-free survivals.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cause of Death. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Male. Middle Aged. Prednisone / administration & dosage. Remission Induction. Rituximab. Survival Analysis. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236611.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


39. Fagnoni P, Milpied N, Limat S, Deconinck E, Nerich V, Foussard C, Colombat P, Harousseau JL, Woronoff-Lemsi MC, Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang: Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin's lymphoma. Pharmacoeconomics; 2009;27(1):55-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin's lymphoma.
  • CHOP) in adults with aggressive non-Hodgkin's lymphoma (NHL).
  • The aim of the study was to evaluate the pharmacoeconomic profile of HDT with PBSCT support relative to standard CHOP therapy as first-line treatment in adults with aggressive NHL.
  • Uncertainty was assessed using non-parametric bootstrap simulations and various scenario analyses.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / economics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy / economics. Cost-Benefit Analysis. Lymphoma, Non-Hodgkin / economics. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation / economics
  • [MeSH-minor] Adult. Cyclophosphamide / economics. Cyclophosphamide / therapeutic use. Doxorubicin / economics. Doxorubicin / therapeutic use. Female. Humans. Male. Prednisolone / economics. Prednisolone / therapeutic use. Randomized Controlled Trials as Topic. Time Factors. Transplantation, Autologous / economics. Vincristine / economics. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Value Health. 2005 Jul-Aug;8(4):462-70 [16091023.001]
  • [Cites] Rev Epidemiol Sante Publique. 2000 Jan;48(1):53-70 [10740085.001]
  • [Cites] Eur J Haematol. 2005 Aug;75(2):116-23 [16000127.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(14):1781-9 [11549432.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1287-95 [15044639.001]
  • [Cites] Ann Oncol. 2006 May;17 Suppl 4:iv8-11 [16702186.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] Health Econ. 1997 Jul-Aug;6(4):327-40 [9285227.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6387-93 [16155024.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):81-4 [10638970.001]
  • [Cites] Presse Med. 1992 Sep 12;21(29):1364-8 [1454765.001]
  • [Cites] Eur J Cancer. 2000 Dec;36(18):2360-7 [11094310.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Bone Marrow Transplant. 2005 Jun;35(12):1149-53 [15880133.001]
  • [Cites] Haematologica. 2005 May;90(5):661-71 [15921381.001]
  • [Cites] Bone Marrow Transplant. 1997 Dec;20(11):975-82 [9422478.001]
  • [Cites] JAMA. 1997 Jun 11;277(22):1802-6 [9178794.001]
  • [Cites] Pharmacoeconomics. 2004;22(4):207-24 [14974872.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):5-10 [8996118.001]
  • [Cites] Health Policy. 1990 Dec;16(3):199-208 [10109801.001]
  • [Cites] N Engl J Med. 2006 Apr 27;354(17):1813-26 [16641398.001]
  • [Cites] Bone Marrow Transplant. 2000 May;25(9):997-1002 [10800070.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1251-6 [11675082.001]
  • [Cites] Pharmacoeconomics. 1999 Mar;15(3):305-11 [10537437.001]
  • [Cites] Pharmacoeconomics. 2007;25(5):365-84 [17488136.001]
  • [Cites] Biometrics. 1989 Sep;45(3):781-95 [2790121.001]
  • [Cites] Ann Intern Med. 1997 Apr 15;126(8):600-7 [9103126.001]
  • [Cites] Bone Marrow Transplant. 1997 Feb;19(3):275-81 [9028558.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):969-73 [7707125.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3302-17 [10986064.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1644-51 [15756658.001]
  • (PMID = 19178124.001).
  • [ISSN] 1170-7690
  • [Journal-full-title] PharmacoEconomics
  • [ISO-abbreviation] Pharmacoeconomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


40. Nicotra G, Manfroi F, Follo C, Castino R, Fusco N, Peracchio C, Kerim S, Valente G, Isidoro C: High expression of cathepsin D in non-Hodgkin's lymphomas negatively impacts on clinical outcome. Dis Markers; 2010;28(3):167-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of cathepsin D in non-Hodgkin's lymphomas negatively impacts on clinical outcome.
  • We investigated whether the level of CD expression influences the progression and the clinical outcome in Non-Hodgkin's Lymphomas (NHLs).
  • In the subgroup of aggressive/high grade of malignancy lymphomas (i.e., DLBCL, FL IIIB and PTCL), the Kaplan-Meier curve revealed a very low cumulative overall survival probability (approximately 20% at 5 year) for patients bearing a NHL with > 40% CD-positive cells compared to that of patients bearing a NHL with < 20% CD-positive cells ( approximately 70% at 5 year).
  • [MeSH-major] Cathepsin D / metabolism. Lymphoma, Non-Hodgkin / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534902.001).
  • [ISSN] 1875-8630
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.23.5 / Cathepsin D
  • [Other-IDs] NLM/ PMC3833244
  •  go-up   go-down


41. Alexandrescu DT, Karri S, Wiernik PH, Dutcher JP: Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease. Leuk Lymphoma; 2006 Apr;47(4):641-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease.
  • Advanced-stage or relapsed/refractory Hodgkin's disease (HD) has a poor prognosis despite aggressive chemotherapy regimens and the use of high-dose therapy with autologous stem cell support.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lomustine / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Mitoxantrone / therapeutic use. Vinblastine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690523.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10CA14958; United States / NCI NIH HHS / CA / P30CA13330
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5V9KLZ54CY / Vinblastine; 7BRF0Z81KG / Lomustine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


42. Navarro JT, Ribera JM, Oriol A, Xicoy B, Mate JL, Sirera G, Lloveras N, Millá F, Feliu E: Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapy. Int J Hematol; 2007 Nov;86(4):337-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapy.
  • In the era of highly active antiretroviral therapy (HAART), the prognosis for acquired immunodeficiency syndrome-related lymphomas (ARL) seems to be similar to that for aggressive B-cell lymphomas in human immunodeficiency virus (HIV)-negative patients.
  • We evaluated the prognostic factors for response and survival in a series of HIV-infected patients with systemic non-Hodgkin's lymphoma (NHL) in the HAART era.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / pathology. Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Cyclophosphamide. Disease-Free Survival. Doxorubicin. Female. HIV / physiology. Humans. Male. Prednisolone. Prognosis. Vincristine


43. Passam FH, Sfiridaki A, Pappa C, Kyriakou D, Petreli E, Roussou PA, Alexandrakis MG: Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment. Int J Lab Hematol; 2008 Feb;30(1):17-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment.
  • Increased angiogenesis has been shown to be a feature of non-Hodgkin lymphomas (NHL).
  • However, by stratification into group of responders vs. non-responders pretreatment IL-8 was significantly increased whereas IL-16 was decreased in the subgroup of complete responders.
  • Both indolent and aggressive B cell lymphomas have increased production of angiogenic mediators and cytokines with IL-8 and IL-16 potentially reflecting the response to treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Interleukins / blood. Lymphoma, B-Cell / blood. Lymphoma, B-Cell / drug therapy. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic. Prognosis. Remission Induction

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190463.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


44. Moser EC, Noordijk EM, van Leeuwen FE, Baars JW, Thomas J, Carde P, Meerwaldt JH, van Glabbeke M, Kluin-Nelemans HC: Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study. Haematologica; 2006 Nov;91(11):1481-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.
  • BACKGROUND AND OBJECTIVES: Second cancer has been associated with non-Hodgkin's Lymphoma (NHL) treatment, but few studies have addressed this issue considering specific treatments.
  • DESIGN AND METHODS: We estimated risk by standardized incidence ratios (SIR) and absolute excess risk (AER) based on general population rates (European Network of Cancer Registries) in 748 patients (aged 15-82 years) treated for aggressive NHL in four successive EORTC (European Organization for Research on Treatment of Cancer) trials.
  • Cancer risk appeared age-related: in young patients high risks were observed for leukemia (SIR 16.7,95% CI 1.4-93.1,AER 5.0), Hodgkin's lymphoma (SIR 60.1,95% CI 12.4-175.2, AER 15.7), colorectal cancer (SIR 12.5, 95% CI 2.6-36.5, AER 14.7) and lung cancer (SIR 15.4; 95% CI 4.2-39.4, AER 19.8), while risk in patients older than 45 years matched than that in the normal population.
  • INTERPRETATION AND CONCLUSIONS: Half of the patients die of aggressive NHL before living long enough to experience second cancer.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / epidemiology. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cohort Studies. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Europe / epidemiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prednisone / adverse effects. Prednisone / therapeutic use. Registries. Retrospective Studies. Risk Factors. Vincristine / adverse effects. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043014.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


45. Sissolak G, Juritz J, Sissolak D, Wood L, Jacobs P: Lymphoma--emerging realities in sub-Saharan Africa. Transfus Apher Sci; 2010 Apr;42(2):141-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma--emerging realities in sub-Saharan Africa.
  • Substantial geographical differences exist for Hodgkin and other lymphoproliferative disorders with these having previously been documented in a report from the lymphoma reclassification project.
  • Median age was 55.2 years 61% were males, 10% had Hodgkin lymphoma and, overall, constitutional symptoms were present in 20%.
  • Median survival in hairy cell leukaemia (n=14), chronic lymphocytic leukaemia-small lymphocytic lymphoma (n=103), Hodgkin (n=41) and follicular lymphoma (n=59) was not reached at the time of analysis and exceeded 36 months.
  • This was followed by 32 months for those with mantle cell (n=7), splenic (n=2) and extranodal marginal cell (n=11), 24 months for T-cell lymphomas (n=24), 20 months for diffuse large B-cell variants (n=88) but only 12 months for the aggressive tumours exemplified by Burkitt (n=7) and lymphoblastic subtypes (n=6).
  • Overall survival at 3 years in each category was compared to the curve for the entire cohort and was 100% in hairy cell leukaemia receiving two chlorodeoxyadenosine and greater than 88% in Hodgkin lymphoma treated according to the German study group protocols (p=0.0004).
  • Corresponding figures for chronic lymphocytic leukaemia-small lymphocytic lymphoma were 82% (p=0.0006), follicular lymphoma 71% (p=0.060), peripheral T-cell lymphoma 43% (p=0.0156), diffuse large B-cell lymphoma 39% (p<0.0001), aggressive tumours 25% (p=0.0002) and for the indolent categories including mantle cell, splenic and extra nodal marginal cell lymphomas 22% (p=0.2023).
  • [MeSH-major] Lymphoma
  • [MeSH-minor] Adolescent. Adult. Africa South of the Sahara / epidemiology. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010. Published by Elsevier Ltd.
  • (PMID = 20149748.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


46. Vellenga E, van Putten WL, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, Verdonck LF, Wijermans PW, van Imhoff GW, Lugtenburg PJ, Huijgens PC: Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood; 2008 Jan 15;111(2):537-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.
  • We evaluated the role of rituximab during remission induction chemotherapy in relapsed aggressive CD20+ non-Hodgkin lymphoma.
  • These results demonstrate improved FFS and PFS for relapsed aggressive B-cell NHL if rituximab is added to the re-induction chemotherapy regimen.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Prospective Studies. Recurrence. Remission Induction. Rituximab. Survival Rate. Transplantation, Autologous


47. Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, Bopp C, Gorschlüter M, Wilhelm M, Birkmann J, Kaiser U, Neubauer A, Florschütz A, Rabe C, Hahn C, Glasmacher AG, Schmidt-Wolf IG: Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest; 2006 Oct;24(6):593-600
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
  • A total of 53 patients with relapsed or resistant aggressive B-cell NHL were analyzed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Prospective Studies. Rituximab. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982464.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; DHAP protocol
  •  go-up   go-down


48. Au WY, Ma SY, Chim CS, Choy C, Loong F, Lie AK, Lam CC, Leung AY, Tse E, Yau CC, Liang R, Kwong YL: Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol; 2005 Feb;16(2):206-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: There were 148 cases, constituting 16.6% (T-cell, n=90, 10.1%, NK-cell, n=58, 6.5%) of all non-Hodgkin lymphomas in this period.
  • Commonest T-cell lymphomas included anaplastic large cell lymphoma (ALCL, n=25, median age 35 years, nodal 60%, stage I/II 60%), peripheral T-cell lymphoma, unspecified (PTCL, n=24, median age 54 years, nodal 42%, stage I/II 42%), and angioimmunoblastic T-cell lymphoma (AILT, n=19, median age 67 years, nodal 95%, stage I/II 26%).
  • AILT, PTCL and ALCL were aggressive with a poor outcome.
  • NK-cell lymphomas were predominantly extranodal (96%) and aggressive, with a frequency much higher than Western patients.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15668271.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Levy O, Deangelis LM, Filippa DA, Panageas KS, Abrey LE: Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer; 2008 Jan 1;112(1):151-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-6 predicts improved prognosis in primary central nervous system lymphoma.
  • BACKGROUND: In systemic non-Hodgkin lymphoma (NHL), tumors that resemble germinal center B-cells are less aggressive than tumors that resemble postgerminal center B-cells.
  • However, the value of B-cell differentiation markers in primary central nervous system lymphoma (PCNSL) is less clear.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis. Proto-Oncogene Proteins c-bcl-6 / analysis
  • [MeSH-minor] Adult. Age Factors. Aged. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17999414.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-6
  •  go-up   go-down


50. Pedersen LM, Klausen TW, Davidsen UH, Johnsen HE: Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Ann Hematol; 2005 Aug;84(8):510-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma.
  • Several lines of evidence suggest that serum levels of interleukin (IL)-6 and vascular endothelial growth factor (VEGF) are independent indicators of long-term outcome in non-Hodgkin's lymphoma (NHL), but the clinical impact of early serial monitoring of these cytokines has not been reported.
  • Serum samples from 64 newly diagnosed patients with aggressive NHL were obtained before the first cycle of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and then weekly until the second cycle was given.
  • [MeSH-major] Interleukin-6 / blood. Lymphoma, Non-Hodgkin / diagnosis. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Inflammation / blood. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prednisone / therapeutic use. Prognosis. Survival Analysis. Treatment Outcome. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15834569.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Vascular Endothelial Growth Factor A; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


51. Al-Abbadi MA, Hattab EM, Tarawneh MS, Amr SS, Orazi A, Ulbright TM: Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: A study of 18 cases. Mod Pathol; 2006 Dec;19(12):1521-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: A study of 18 cases.
  • The most common type of primary testicular lymphoma is diffuse large B-cell type, which has the potential for aggressive clinical behavior.
  • Diffuse large B-cell lymphoma can be further subclassified into two major prognostic categories: germinal center B-cell-like and nongerminal center B-cell-like.
  • The aim of this study was to stratify primary testicular lymphoma of the diffuse large B-cell type according to this scheme.
  • Immunohistochemical stains for CD10, Bcl-6 and MUM1 were performed on 18 cases of primary testicular lymphoma of diffuse large B-cell type.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Non-Hodgkin / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. DNA-Binding Proteins / analysis. Humans. Immunoenzyme Techniques. Interferon Regulatory Factors / analysis. Male. Middle Aged. Neoplasm Staging. Neprilysin / analysis. Prognosis. Survival Rate. Testis / chemistry. Testis / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998463.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


52. Laudenschlager MD, Geis MC: An aggressive "double-hit" lymphoma occurring in a 42-year-old male with both MYC and t(14;18) translocations. S D Med; 2010 Sep;63(9):311-3, 315
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An aggressive "double-hit" lymphoma occurring in a 42-year-old male with both MYC and t(14;18) translocations.
  • We describe a 42-year-old male who was in good health until he presented with a high grade B-cell non-Hodgkin lymphoma/leukemia that had both MYC and t(14;18) translocations.
  • This process has now been classified as "B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma," according to the 2008 World Health Organization Classification of Tumours of Haematopoitic and Lymphoid Tissues.
  • Prognosis is generally reported as poor in these aggressive "double-hit" lymphomas.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-myc / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Humans. Immunohistochemistry. Immunophenotyping. Karyotyping. Ki-67 Antigen / metabolism. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20860118.001).
  • [ISSN] 0038-3317
  • [Journal-full-title] South Dakota medicine : the journal of the South Dakota State Medical Association
  • [ISO-abbreviation] S D Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


53. Wadhwa PD, Fu P, Koc ON, Cooper BW, Fox RM, Creger RJ, Bajor DL, Bedi T, Laughlin MJ, Payne J, Gerson SL, Lazarus HM: High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality. Biol Blood Marrow Transplant; 2005 Jan;11(1):13-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
  • Over a 10-year period (January 1993 to October 2002), 101 relapsed or refractory non-Hodgkin lymphoma patients were treated at our center with high-dose chemotherapy and autologous transplantation.
  • Thirty-two patients had indolent (low-grade), 42 had aggressive (intermediate-grade), and 27 had very aggressive (high-grade) non-Hodgkin lymphoma.
  • Four patients (4%) died within 30 days of stem cell infusion (1 pulmonary embolism, 2 septicemias with multiorgan failure, and 1 progressive lymphoma).
  • BEP with or without IFR is a highly effective and well-tolerated regimen in the relapsed/refractory lymphoma setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Aged. Carmustine / administration & dosage. Cisplatin / administration & dosage. Drug Resistance, Neoplasm. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasms, Second Primary / etiology. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Radiotherapy, Adjuvant / mortality. Salvage Therapy / methods. Salvage Therapy / mortality. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15625540.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


54. Novakovic BJ, Novakovic S, Frkovic-Grazio S: A single-center report on clinical features and treatment response in patients with intestinal T cell non-Hodgkin's lymphomas. Oncol Rep; 2006 Jul;16(1):191-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center report on clinical features and treatment response in patients with intestinal T cell non-Hodgkin's lymphomas.
  • Intestinal T cell lymphomas are rare, but highly aggressive in their clinical course.
  • Generally diagnosed in advanced stages and presenting as surgical emergencies, they also respond poorly to standard anti-lymphoma therapies.
  • Ten (67%) patients had enteropathy-associated T cell lymphoma (EATL) and 5 (33%) had peripheral T cell lymphoma (PTCL).
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Time Factors. Treatment Outcome

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786145.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


55. Nickelsen M, Ziepert M, Zeynalova S, Glass B, Metzner B, Leithaeuser M, Mueller-Hermelink HK, Pfreundschuh M, Schmitz N: High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol; 2009 Dec;20(12):1977-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
  • DESIGN AND METHODS: We treated patients <61 years with high-risk aggressive lymphoma with four to six courses of dose-escalated CHOP plus etoposide (MegaCHOEP) necessitating repeated ASCT.
  • Outcomes of patients with mature T-NHL (excluding anaplastic lymphoma kinase-positive anaplastic large cell lymphoma) and aggressive B-NHL were compared using multivariate Cox regression analysis.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19570965.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Clinical Trial, Phase III; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


56. Ren X, Jiang X, Wen B: [Clinical analysis of primary nasal cavity-nasal sinuses T/NK cell lymphoma]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Mar;22(5):220-1, 225
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of primary nasal cavity-nasal sinuses T/NK cell lymphoma].
  • OBJECTIVE: To investigate the clinical feature, diagnosis, treatment and prognosis of primary nasal cavity-nasal sinuses T/NK cell lymphoma.
  • METHOD: Twenty-six patients with primary nasal cavity-nasal sinuses T/NK cell lymphoma were retrospectively analyzed.
  • CONCLUSION: The primary nasal cavity-nasal sinuses T/NK cell lymphomas are a distinct category of the non-Hodgkin's lymphoma (NHL).
  • They appear to carry a high malignancy and pursue a aggressive course.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Lymphoma, T-Cell. Nose Neoplasms. Paranasal Sinus Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Killer Cells, Natural. Male. Middle Aged. Nasal Cavity. Paranasal Sinuses. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18476612.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


57. Intragumtornchai T, Bunworasate U, Nakorn TN, Rojnuckarin P: Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Jul;47(7):1306-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
  • With currently available combination chemotherapy regimens, the outcome of the patients newly diagnosed with aggressive non-Hodgkin's lymphoma (NHL) identified as 'high' and 'high-intermediate' risk groups according to the international prognostic index (IPI) is still unsatisfactory and a more innovative therapy is urgently required to improve the survival of the patients.
  • The purpose of this study was to compare the efficacy of rituximab given in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and ESHAP (etoposide, methylprednisolone, high-dose Ara-C, cisplatin) vs CHOP-ESHAP and upfront high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) vs standard CHOP in patients aged < or = 65 years old newly diagnosed with 'high' and 'high-intermediate' risk aggressive lymphoma enrolled onto two consecutive treatment trials at the institute.
  • Between May 1995 - July 2002, 84 patients, aged 15 - 65 years old, with newly diagnosed aggressive NHL and an age-adjusted IPI of 2 or 3 were enrolled.
  • It is concluded that rituximab-ESHAP-CHOP is superior over standard CHOP and fares comparably to upfront HDT/ASCT in previously untreated patients with aggressive lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Methylprednisolone / administration & dosage. Middle Aged. Prednisone / administration & dosage. Proportional Hazards Models. Rituximab. Time Factors. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923561.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; X4W7ZR7023 / Methylprednisolone; CHOP protocol; ESAP protocol
  •  go-up   go-down


58. Kim SW, Tanimoto TE, Hirabayashi N, Goto S, Kami M, Yoshioka S, Uchida T, Kishi K, Tanaka Y, Kohno A, Kasai M, Higuchi M, Kasai M, Mori S, Fukuda T, Izutsu K, Sao H, Ishikawa T, Ichinohe T, Takeuchi K, Tajima K, Tanosaki R, Harada M, Taniguchi S, Tobinai K, Hotta T, Takaue Y: Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood; 2006 Jul 1;108(1):382-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan.
  • We retrospectively surveyed the data of 233 patients who underwent myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) for non-Hodgkin lymphoma (NHL).
  • One hundred ninety-three (83%) received a total body irradiation (TBI)-based regimen, and 40 (17%) received a non-TBI-based regimen.
  • Relapse or progression of lymphoma was observed in 21%.
  • The 2-year overall survival rates of the patients with indolent (n = 38), aggressive (n = 111), and lymphoblastic lymphoma (n = 84) were 57%, 42%, and 41%, respectively.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Acute Disease. Adult. Disease Progression. Female. Graft vs Host Disease / therapy. Health Surveys. Humans. Japan / epidemiology. Male. Multivariate Analysis. Neoplasm Staging. Prognosis. Recurrence. Remission Induction. Retrospective Studies. Survival Rate. Transplantation Conditioning. Transplantation, Homologous. Treatment Outcome


59. Lazarus HM, Carreras J, Boudreau C, Loberiza FR Jr, Armitage JO, Bolwell BJ, Freytes CO, Gale RP, Gibson J, Hale GA, Inwards DJ, LeMaistre CF, Maharaj D, Marks DI, Miller AM, Pavlovsky S, Schouten HC, van Besien K, Vose JM, Bitran JD, Khouri IF, McCarthy PL, Yu H, Rowlings P, Serna DS, Horowitz MM, Rizzo JD, Center For International Blood & Marrow Transplant Research (CIBMTR): Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant; 2008 Dec;14(12):1323-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR).
  • To compare the clinical outcomes of older (age > or =55 years) non-Hodgkin lymphoma (NHL) patients with younger NHL patients (<55 years) receiving autologous hematopoietic cell transplantation (HCT) while adjusting for patient-, disease-, and treatment-related variables, we compared autologous HCT outcomes in 805 NHL patients aged > or =55 years to 1949 NHL patients <55 years during the years 1990-2000 using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR).
  • In multivariate analysis, older patients with aggressive histologies were 1.86 times (95% confidence interval [CI] 1.43-2.43, P < .001) more likely than younger patients to experience treatment-related mortality (TRM).
  • Relative death risks were 1.33 times (CI 1.04-1.71, P = .024) and 1.50 times (CI 1.33-16.9, P < .001) higher in older compared to younger patients with follicular grade I/II and aggressive histologies, respectively.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3325-33 [10552941.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):840-6 [18541205.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(2A):204-10 [10816029.001]
  • [Cites] Bone Marrow Transplant. 2000 Oct;26(7):737-41 [11042654.001]
  • [Cites] Blood. 2000 Nov 1;96(9):2934-42 [11049969.001]
  • [Cites] Bone Marrow Transplant. 2001 Mar;27(6):593-9 [11319588.001]
  • [Cites] Blood. 2002 May 1;99(9):3158-62 [11964278.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Jun;9(6):383-8 [12813446.001]
  • [Cites] Blood. 2003 Jul 1;102(1):31-5 [12595317.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Feb;10(2):116-27 [14750077.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1258-65 [15126323.001]
  • [Cites] Vital Health Stat 13. 1991 Sep;(108):1-236 [1720910.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5432s-5440s [1394149.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] N Engl J Med. 1994 Oct 20;331(16):1063-7 [8090167.001]
  • [Cites] Bone Marrow Transplant. 1994 Dec;14(6):981-7 [7711677.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Lancet. 1996 Feb 10;347(8998):353-7 [8598700.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1327-32 [8648391.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):18-25 [8996120.001]
  • [Cites] Bone Marrow Transplant. 1997 Jan;19(1):31-5 [9012928.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):445-50 [9053464.001]
  • [Cites] N Engl J Med. 1997 Mar 27;336(13):897-904 [9070469.001]
  • [Cites] Clin Geriatr Med. 1997 May;13(2):251-63 [9115450.001]
  • [Cites] Bone Marrow Transplant. 1997 Apr;19(7):671-8 [9156243.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):48-55 [9440722.001]
  • [Cites] Bone Marrow Transplant. 1998 Jun;21(12):1193-6 [9674850.001]
  • [Cites] Stat Med. 1999 Jun 30;18(12):1489-500 [10398287.001]
  • [Cites] Bone Marrow Transplant. 1999 Jun;23(12):1273-8 [10414915.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(11):1017-22 [16633361.001]
  • [Cites] Ann Oncol. 2008 Jun;19(6):1166-71 [18272911.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1588-93 [10688812.001]
  • (PMID = 19041053.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24 CA076518-11; United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS83336; NLM/ PMC2638759
  •  go-up   go-down


60. Ioannidou-Papagiannaki E, Diamantidis MD, Livanis I, Klonizakis P, Haralambidou-Vranitsa S, Vlachaki E, Venizelos I, Klonizakis I: Fatal chylous ascites, pericarditis and extensive venous thrombosis, due to an aggressive T cell non-Hodgkin lymphoma. Ann Hematol; 2009 Apr;88(4):371-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal chylous ascites, pericarditis and extensive venous thrombosis, due to an aggressive T cell non-Hodgkin lymphoma.
  • [MeSH-major] Chylous Ascites / etiology. Lymphoma, T-Cell / complications. Pericarditis / etiology. Venous Thrombosis / etiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Humans. Male


61. Laatiri MA, Elloumi M, Ali ZB, Ben Othmen T, Msadek F, Toumi N, Bouaouina N, Daoud J, Maalej M, Ghannem H, Meddeb B: [Tunisian experience in the treatment of aggressive non Hodgkin's lymphoma in adults: about 337 patients]. Bull Cancer; 2010 Apr;97(4):409-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tunisian experience in the treatment of aggressive non Hodgkin's lymphoma in adults: about 337 patients].
  • From January 1997 to December 2005, 337 patients with aggressive non Hodgkin's lymphoma were treated with one of the two successive multicentric non randomized protocols established in Tunisia.
  • Most patients had diffuse large cell lymphoma with B phenotype in 86% and T in 14%.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Epirubicin / administration & dosage. Etoposide / administration & dosage. Female. Hematopoietic Stem Cell Transplantation / methods. Humans. Karnofsky Performance Status. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Middle Aged. Prednisolone / administration & dosage. Prednisone / administration & dosage. Prospective Studies. Remission Induction / methods. Rituximab. Stem Cell Transplantation. Survival Analysis. Tunisia. Vincristine / administration & dosage. Young Adult

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20374978.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 3Z8479ZZ5X / Epirubicin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; CEOP protocol 2; CHOEP protocol; CHOP protocol
  •  go-up   go-down


62. Teye K, Arima N, Nakamura Y, Sakamoto K, Sueoka E, Kimura H, Tsuneoka M: Expression of Myc target gene mina53 in subtypes of human lymphoma. Oncol Rep; 2007 Oct;18(4):841-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Myc target gene mina53 in subtypes of human lymphoma.
  • We studied Mina53 expression in lymphoma subtypes to examine its diagnostic significance and its possible role in lymphoma-genesis.
  • Surgical cases of 28 lymphoma and 4 non-neoplastic tissues were stained immunochemically using anti-Mina53 monoclonal antibody.
  • Mina53 expression correlated well with c-Myc expression in lymphoma, suggesting that c-Myc is a controlling factor for mina53 expression also in lymphomas.
  • Although the expression of Mina53 as well as c-Myc was less frequent in lymphoma compared with those of colon and ESCC, increased expression of Mina53 was found in Burkitt-like lymphoma (1/1), Hodgkin's lymphoma (3/5), diffuse large B cell lymphoma (DLBCL) (5/13), lymphomas with a transition from follicular to DLBCL (1/2), with none in follicular (0/4) and T cell lymphoma (0/3).
  • Analyses of the data suggested that Mina53 was frequently expressed in aggressive types of B cell lymphoma.
  • These results suggest that although Mina53 expression is not prominent in lymphoma in general, it may be related to tumor progression of B cell lymphoma.
  • [MeSH-major] Burkitt Lymphoma / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Follicular / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Non-Hodgkin / metabolism. Nuclear Proteins / metabolism. Proto-Oncogene Proteins c-myc / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Lymphocytes / metabolism. Lymphocytes / pathology. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786344.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / MINA protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


63. Darom A, Gomatos IP, Leandros E, Chatzigianni E, Panousopoulos D, Konstadoulakis MM, Androulakis G: Molecular markers (PECAM-1, ICAM-3, HLA-DR) determine prognosis in primary non-Hodgkin's gastric lymphoma patients. World J Gastroenterol; 2006 Mar 28;12(12):1924-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular markers (PECAM-1, ICAM-3, HLA-DR) determine prognosis in primary non-Hodgkin's gastric lymphoma patients.
  • AIM: To investigate the prognostic significance of PECAM-1, ICAM-3 and HLA-DR antigens in patients with primary non-Hodgkin's gastric lymphoma.
  • METHODS: We immunohistochemically studied PECAM-1, ICAM-3 and HLA-DR antigen expression in 36 B-cell MALT-type primary gastric lymphoma patients.
  • Ten non-malignant and ten healthy gastric tissue specimens were used as controls.
  • RESULTS: HLA-DR antigen expression was detected in 33 gastric lymphoma patients (91.7%) and 6 non-malignant patients (54.5%).
  • ICAM-3 expression was observed on the tumor cells of 17 patients (47.2%), while 5 non-malignant patients (50%) were stained positive as well.
  • Their combined use may help us to identify high-risk patients who could benefit from more aggressive therapeutic protocols.
  • [MeSH-major] Antigens, CD / analysis. Antigens, CD31 / analysis. Cell Adhesion Molecules / analysis. HLA-DR Antigens / analysis. Lymphoma, Non-Hodgkin / chemistry. Stomach Neoplasms / chemistry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 1991 Feb;2(1):47-54 [1912518.001]
  • [Cites] Eur J Clin Invest. 1990 Oct;20(5):481-6 [2124977.001]
  • [Cites] Lancet. 1992 Nov 7;340(8828):1120-4 [1279332.001]
  • [Cites] Nature. 1992 Dec 3;360(6403):481-4 [1448173.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] J Exp Med. 1993 Aug 1;178(2):449-60 [8340753.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):371-4 [7690738.001]
  • [Cites] Eur J Immunol. 1993 Nov;23(11):2799-806 [8223855.001]
  • [Cites] J Biol Chem. 1995 Jan 13;270(2):877-84 [7822326.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):706-18; discussion 718-20 [7794075.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1196-200 [7590692.001]
  • [Cites] Oncology. 1996 Mar-Apr;53(2):127-32 [8604238.001]
  • [Cites] Leukemia. 1996 May;10(5):907-8 [8656688.001]
  • [Cites] Br J Oral Maxillofac Surg. 1996 Feb;34(1):37-41 [8645680.001]
  • [Cites] J Mol Med (Berl). 1996 Jul;74(7):353-63 [8841948.001]
  • [Cites] Tissue Antigens. 1996 Oct;48(4 Pt 1):271-7 [8946680.001]
  • [Cites] Virchows Arch. 1996 Dec;429(6):377-82 [8982383.001]
  • [Cites] Am J Clin Pathol. 1997 May;107(5):534-41 [9128265.001]
  • [Cites] Vet Pathol. 1997 Jan;34(1):61-73 [9150551.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):326-9 [9221813.001]
  • [Cites] Int J Cancer. 1997 Dec 19;74(6):582-7 [9421352.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):31-6 [9516949.001]
  • [Cites] Tissue Cell. 1998 Jun;30(3):377-82 [10091339.001]
  • [Cites] APMIS. 1999 Apr;107(4):383-8 [10230691.001]
  • [Cites] Microvasc Res. 1999 May;57(3):292-7 [10329255.001]
  • [Cites] Oncology. 1985;42(2):97-103 [3887261.001]
  • [Cites] Immunobiology. 1985 Apr;169(3):228-49 [3873401.001]
  • [Cites] Eur J Immunol. 1986 Feb;16(2):172-81 [2420606.001]
  • [Cites] Int J Cancer. 1986 Oct 15;38(4):459-64 [2428757.001]
  • [Cites] Ann Surg. 1987 Jun;205(6):634-40 [3592805.001]
  • [Cites] J Clin Pathol. 1987 Jul;40(7):760-5 [3305585.001]
  • [Cites] J Clin Pathol. 1987 Sep;40(9):948-58 [3312304.001]
  • [Cites] Blood. 2000 Mar 15;95(6):1900-10 [10706853.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(3):345-57 [10721489.001]
  • [Cites] In Vivo. 2000 Jan-Feb;14(1):199-208 [10757078.001]
  • [Cites] World J Surg. 2000 May;24(5):608-14 [10787085.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2000;48(3):201-4 [10912626.001]
  • [Cites] Lung Cancer. 2000 Sep;29(3):169-77 [10996419.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1641-9 [11117785.001]
  • [Cites] Pathologica. 2000 Dec;92(6):503-15 [11234301.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1258-64 [11483337.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):1202-5 [11490834.001]
  • [Cites] Int J Cancer. 2001 Nov15;94(4):599-604 [11745451.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1185-91 [12006536.001]
  • [Cites] Surgery. 2002 Jul;132(1):20-6 [12110791.001]
  • [Cites] Br J Surg. 1970 Dec;57(12):877-83 [5487028.001]
  • [Cites] Science. 1981 Jun 12;212(4500):1229-38 [6165083.001]
  • [Cites] J Cell Biol. 1982 Dec;95(3):974-81 [6185506.001]
  • [Cites] Cell. 1984 Jan;36(1):1-13 [6198089.001]
  • [Cites] Br Med Bull. 1987 Jan;43(1):217-27 [3315098.001]
  • [Cites] Biochim Biophys Acta. 1989 Feb;948(3):305-26 [2465781.001]
  • [Cites] Scand J Immunol. 1989 Aug;30(2):129-64 [2474849.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1208-17 [2670184.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1154-7 [2400966.001]
  • [Cites] Surg Clin North Am. 1992 Apr;72(2):423-31 [1549801.001]
  • (PMID = 16610000.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Cell Adhesion Molecules; 0 / HLA-DR Antigens; 0 / ICAM3 protein, human
  • [Other-IDs] NLM/ PMC4087519
  •  go-up   go-down


64. Martí-Carvajal AJ, Cardona AF, Rodríguez ML: Interventions for treating AIDS-associated Hodgkin s lymphoma in treatment-naive adults. Cochrane Database Syst Rev; 2007;(2):CD006149
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventions for treating AIDS-associated Hodgkin s lymphoma in treatment-naive adults.
  • BACKGROUND: Hodgkin's disease (HD) is the most common non-AIDS-defining malignancy in HIV-infected patients.
  • Its unusually aggressive tumour behaviour includes a higher frequency of unfavourable histologic subtypes, high-stage and extranodal involvement by the time of presentation (anal canal, stomach), and poor therapeutic outcome, in comparison with HD outside the HIV setting.
  • OBJECTIVES: To assess the effects of different interventions for treating AIDS-associated Hodgkin's disease including chemotherapy, bone marrow transplantation (BMT), and gene therapy on overall survival and disease-free survival in treatment-naive adults with AIDS.
  • [MeSH-major] Lymphoma, AIDS-Related / therapy
  • [MeSH-minor] Adult. Humans

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17443616.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 75
  •  go-up   go-down


65. Vignot S, Ledoussal V, Nodiot P, Bourguignat A, Janvier M, Mounier N, Chérel P, Floiras JL, Turpin F: Non-Hodgkin's lymphoma of the breast: a report of 19 cases and a review of the literature. Clin Lymphoma; 2005 Jun;6(1):37-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the breast: a report of 19 cases and a review of the literature.
  • PURPOSE: Non-Hodgkin's lymphoma of the breast represents 0.04%-0.50% of malignant lesions of the mammary gland.
  • MATERIALS AND METHODS: Between 1982 and 1997, 19 patients with breast lymphoma were diagnosed, treated, and followed at this institution.
  • All but one were cases of aggressive B-cell lymphoma.
  • [MeSH-major] Breast Neoplasms / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / mortality. Breast Neoplasms, Male / therapy. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989705.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


66. Shah JJ, Meredith R, Shen S, Nabors B, Lobuglio A, Yester M, Forero A: Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy. Clin Lymphoma Myeloma; 2006 Nov;7(3):236-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy.
  • Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma arising within and confined to the central nervous system and, unlike other primary brain tumors, is very responsive to treatment.
  • Aggressive management can lead to prolonged remissions or cures.
  • Radioimmunotherapy has a growing role in the management of systemic non-Hodgkin lymphoma but has not been evaluated in PCNSL.
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Central Nervous System Neoplasms / therapy. Lymphoma / radiotherapy. Lymphoma / therapy. Radioimmunotherapy / methods
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Blood-Brain Barrier. Brain / pathology. Humans. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / therapy. Magnetic Resonance Imaging / methods. Male. Methotrexate / therapeutic use. Prognosis. Remission Induction

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17229341.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / ibritumomab tiuxetan; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


67. Jegalian AG, Facchetti F, Jaffe ES: Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol; 2009 Nov;16(6):392-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Normally found in small quantities in primary and secondary lymphoid organs, PDCs accumulate in a variety of inflammatory conditions, including Kikuchi-Fujimoto lymphadenopathy, hyaline-vascular Castleman disease, and autoimmune diseases, and in certain malignancies such as classical Hodgkin lymphoma and carcinomas.
  • Demonstrating potential for neoplastic transformation reflective of varying stages of maturation, clonal proliferations range from PDC nodules most commonly associated with chronic myelomonocytic leukemia to the rare but highly aggressive malignancy now known as blastic plasmacytoid dendritic cell neoplasm (BPDCN).
  • Formerly called blastic natural killer cell lymphoma or CD4/CD56 hematodermic neoplasm, BPDCN, unlike natural killer cell lymphomas, is not associated with Epstein-Barr virus infection and is generally not curable with treatment regimens for non-Hodgkin lymphomas.
  • In fact, this entity is no longer considered to be a lymphoma and instead represents a unique precursor hematopoietic neoplasm.
  • Acute leukemia therapy regimens may lead to sustained clinical remission of BPDCN, with bone marrow transplantation in first complete remission potentially curative in adult patients.
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Lineage. Child. Child, Preschool. Female. Humans. Leukemia, Myeloid / pathology. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / pathology. Male. Toll-Like Receptors / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19851130.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Toll-Like Receptors
  • [Number-of-references] 151
  •  go-up   go-down


68. Ríos A, Torres J, Roca MJ, Galindo PJ, Alonso JL, Parrilla P: [Primary thymic lymphomas]. Rev Clin Esp; 2006 Jul-Aug;206(7):326-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: Ten LPTs--four Hodgkin's and six non-Hodgkin's (4 primary mediastinal B lymphomas [PMBLs] and 2 lymphoblastic T lymphomas [LTLs]--were reviewed.
  • RESULTS: The initial diagnostic suspicion in the Hodgkin's lymphomas was thymoma in two cases and lymphoma in the other 2.
  • The non-Hodgkin's lymphomas had large tumors and short evolution.
  • CONCLUSIONS: In a patient with thymic tumour with a preoperative or intraoperative study suspected of having a lymphoma, it is necessary to do a biopsy and not resective surgery, to avoid unnecessary resections and morbidity.
  • PTLs are uncommon but aggressive, principally the non-Hodgkin's lymphomas.
  • [MeSH-major] Hodgkin Disease / radiography. Lymphoma, Non-Hodgkin / radiography. Thymus Neoplasms / radiography
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Transplantation / methods. Combined Modality Therapy. Female. Humans. Male. Thymectomy

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831379.001).
  • [ISSN] 0014-2565
  • [Journal-full-title] Revista clínica española
  • [ISO-abbreviation] Rev Clin Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


69. Baldissera RC, Nucci M, Vigorito AC, Maiolino A, Simões BP, Lorand-Metze I, Aranha FJ, Miranda EC, Pagnano KB, Ruiz MA, Moraes AA, De Souza CA: Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: a prospective randomized GEMOH report. Acta Haematol; 2006;115(1-2):15-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: a prospective randomized GEMOH report.
  • This prospective multicenter randomized trial compares conventional with early intensification with high-dose sequential chemotherapy (HDS) and autologous stem cell transplantation (ASCT) as frontline therapy in high-risk non-Hodgkin lymphomas (NHL).
  • Newly diagnosed patients with aggressive high-risk [intermediate-high (HI) and high-risk (HR)] NHL according to the international prognosis index (IPI) were randomized to receive 12-week VACOP-B (arm A, 27 patients) or 6-week VACOP-B followed by HDS and ASCT (arm B, 29 patients).
  • Abbreviated chemotherapy followed by intensification with HDS-ASCT does not seem to be superior to conventional chemotherapy in HI/HR aggressive NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prognosis. Remission Induction. Risk Factors. Transplantation, Autologous. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16424644.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; VACOP-B protocol
  •  go-up   go-down


70. Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE: High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant; 2006 Jul;12(7):703-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
  • Allogeneic hematopoietic cell transplantation (HCT) has been shown to be curative in a group of patients with aggressive non-Hodgkin lymphoma (NHL).
  • CBV is an effective preparative regimen for patients with aggressive NHL who undergo allogeneic HCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Carmustine / administration & dosage. Cause of Death. Combined Modality Therapy / methods. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Female. Graft vs Host Disease / mortality. Histocompatibility Testing. Humans. Male. Middle Aged. Survival Analysis. Transplantation, Homologous / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785059.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; U68WG3173Y / Carmustine; CBV protocol
  •  go-up   go-down


71. Widmann TA, Herrmann M, Taha N, König J, Pfreundschuh M: Short telomeres in aggressive non-Hodgkin's lymphoma as a risk factor in lymphomagenesis. Exp Hematol; 2007 Jun;35(6):939-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short telomeres in aggressive non-Hodgkin's lymphoma as a risk factor in lymphomagenesis.
  • METHODS: We designed an (age-) matched pair analysis that compared telomere length in nonmalignant peripheral leukocytes from previously untreated patients who recently developed an aggressive non-Hodgkin's lymphoma, with leukocytes from healthy individuals.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Chromosomes, Human / metabolism. Lymphoma, Non-Hodgkin / metabolism. Telomere / metabolism
  • [MeSH-minor] Adult. B-Lymphocytes / metabolism. B-Lymphocytes / pathology. Female. Granulocytes / metabolism. Granulocytes / pathology. Humans. Male. Oxidative Stress / genetics. Risk Factors. T-Lymphocytes / metabolism. T-Lymphocytes / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17533048.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


72. Gross SA, Zhu X, Bao L, Ryder J, Le A, Chen Y, Wang XQ, Irons RD: A prospective study of 728 cases of non-Hodgkin lymphoma from a single laboratory in Shanghai, China. Int J Hematol; 2008 Sep;88(2):165-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of 728 cases of non-Hodgkin lymphoma from a single laboratory in Shanghai, China.
  • The frequency of non-Hodgkin lymphoma was 87.6% (n = 728) and Hodgkin lymphoma was 12.4% (n = 103).
  • The most prevalent NHL subtypes diagnosed using WHO criteria were diffuse large B cell lymphoma (DLBCL), precursor B lymphoblastic leukemia/lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
  • Consistent with previous reports, our findings indicate a decrease in the frequency of follicular lymphoma and an increase in T cell neoplasms compared to the West.
  • Precursor T lymphoblastic leukemia/lymphoma, anaplastic large T cell lymphoma, aggressive NK cell leukemia, angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma were prominent subtypes of T cell NHL.
  • [MeSH-major] Asian Continental Ancestry Group / statistics & numerical data. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / ethnology
  • [MeSH-minor] Adult. China / epidemiology. DNA, Neoplasm / analysis. Humans. In Situ Hybridization, Fluorescence. Prevalence. Prospective Studies. Urban Population / statistics & numerical data. World Health Organization

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1984 Aug 15;34(2):143-8 [6381328.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1091-6 [15205204.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1813-9 [8859197.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1151-68 [7858247.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Cancer Lett. 1999 Jan 8;135(1):73-81 [10077224.001]
  • [Cites] Cancer. 1994 Jul 1;74(1):174-81 [8004573.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Oct;5(5):983-1001 [1938764.001]
  • [Cites] Int J Hematol. 2007 Jan;85(1):18-25 [17261497.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1360-4 [17326056.001]
  • [Cites] Hum Pathol. 1987 Sep;18(9):924-8 [3497862.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Dec;13(4):323-32 [16280661.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1586-92 [11013375.001]
  • [Cites] Br J Haematol. 1999 Nov;107(2):353-6 [10583224.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2005 Jan;34(1):22-7 [15796877.001]
  • [Cites] Pathol Int. 2002 Jan;52(1):1-12 [11940200.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):114-41; discussion 200-2 [12196212.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):806-12 [9708949.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:1-39 [17405121.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • (PMID = 18648906.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


73. Müller-Beissenhirtz H, Kasper C, Nückel H, Dührsen U: Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study. Ann Hematol; 2005 Nov;84(12):796-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study.
  • The optimum therapy for patients with relapsed or refractory aggressive non-Hodgkin's lymphomas (NHL) not qualifying for platinum-based and/or high-dose chemotherapy is not known.
  • GVP shows substantial activity in poor prognosis relapsed or refractory aggressive lymphomas and is generally well tolerated, but haematological toxicity is dose limiting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Humans. Infection / etiology. Infection / mortality. Leukopenia / etiology. Leukopenia / mortality. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Prospective Studies. Recurrence. Remission Induction. Thrombocytopenia / etiology. Thrombocytopenia / mortality. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16041531.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine; VB0R961HZT / Prednisone
  •  go-up   go-down


74. Mihaljević B, Nedeljkov-Janćić R, Cemerikić-Martinović V, Babić D, Colović M: Ki-67 proliferative marker in lymph node aspirates of patients with non-Hodgkin's lymphoma. Med Oncol; 2006;23(1):83-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-67 proliferative marker in lymph node aspirates of patients with non-Hodgkin's lymphoma.
  • Proliferative activity of lymphoma cells was tested by immunocytochemical staining with Ki-67 monoclonal antibody in 63 aspirates of peripheral lymph nodes sampled from patients suffering from non-Hodgkin's lymphoma.
  • Referring to the dominant cell population in nodal aspirates, a rising trend of Ki-67 proliferative marker was noted from the small cells (X = 13.20) and small cells with notched nucleus (X = 43.52) and large cells (X = 79.47) with histopathologic equivalents corresponding to aggressive lymphoma.
  • Statistically significant correlation of Ki-67 with cytomorphology and REAL-immunocytochemical classification of lymphoma was confirmed, but not with the IPI index.
  • In order to determine the prognostic importance of Ki-67 marker, the patients were classified into those with low Ki-67 (<20% of proliferating cells), mean proliferation index Ki-67 (range 20-59%), and high proliferative index Ki-67 (positive in over 60% of lymphoma cells).
  • [MeSH-major] Ki-67 Antigen / analysis. Lymph Nodes / chemistry. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1460-6 [8123837.001]
  • [Cites] Diagn Cytopathol. 1995 May;12(3):234-8; discussion 238-40 [7621718.001]
  • [Cites] Pathol Res Pract. 2001;197(6):385-93 [11432665.001]
  • [Cites] Cancer. 2004 Jun 25;102(3):174-85 [15211477.001]
  • [Cites] J Clin Pathol. 1990 Apr;43(4):325-8 [2341568.001]
  • [Cites] Blood. 1988 Apr;71(4):1157-60 [3281723.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4085-9 [8943841.001]
  • [Cites] Cancer. 1988 Sep 1;62(5):989-93 [3409179.001]
  • [Cites] Am J Pathol. 1991 Apr;138(4):867-73 [2012175.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):414-9 [15085385.001]
  • [Cites] Acta Cytol. 2004 Mar-Apr;48(2):119-26 [15085740.001]
  • [Cites] Pathol Int. 2004 Sep;54(9):667-74 [15363034.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):97-104 [15354733.001]
  • [Cites] Cytopathology. 2000 Oct;11(5):290-301 [11014656.001]
  • [Cites] Acta Oncol. 2002;41(1):36-43 [11990516.001]
  • [Cites] Med Oncol. 2001;18(1):15-22 [11778965.001]
  • [Cites] J Pathol. 1988 Mar;154(3):223-35 [2450981.001]
  • [Cites] Verh Dtsch Ges Pathol. 1992;76:117-21 [1283240.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):385-93 [14681948.001]
  • [Cites] J Clin Pathol. 1998 Mar;51(3):189-96 [9659258.001]
  • [Cites] World J Gastroenterol. 2004 Jul 1;10(13):1862-6 [15222024.001]
  • [Cites] Hematol Oncol. 1984 Oct-Dec;2(4):365-71 [6396192.001]
  • (PMID = 16645233.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


75. Ramírez V P, Ocqueteau T M, Alvarez Z M, Bertín C-M P, Lira V P, Bustos C M, Besa de C P: [Long term results for intermediate and high grade localized non Hodgkin lymphoma, treated with chemotherapy and radiotherapy]. Rev Med Chil; 2006 Nov;134(11):1409-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long term results for intermediate and high grade localized non Hodgkin lymphoma, treated with chemotherapy and radiotherapy].
  • BACKGROUND: Treatment of intermediate and high grade non-Hodgkin lymphoma (NHL) includes chemotherapy with or without radiotherapy, depending on the clinical stage.
  • AIM: To evaluate the treatment results including overall survival (OS) and event-free survival (EFS) in localized aggressive NHL patients treated at the Pontificia Universidad Católica de Chile, Clinical Hospital.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy / methods. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Prognosis. Radiotherapy, Adjuvant. Recurrence. Retrospective Studies. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277854.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; EPOCH protocol
  •  go-up   go-down


76. Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, Bisi G: FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging; 2008 Mar;52(1):9-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
  • AIM: Identification of bone marrow disease (BMD) is a crucial step in the diagnostic work-up of patients with lymphoma.
  • In lymphoma staging, bone marrow biopsy (BMb) is considered as the gold standard, despite its limitations.
  • The aim of this study was to compare the usefulness of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography (FDG-PET) vs BMb in the detection of BMD in patients with Hodgkin's disease (HL) or aggressive non-Hodgkin's lymphoma (NHL) and its impact on therapy.
  • METHODS: A total of 194 consecutive patients with malignant lymphoma were referred for staging.
  • [MeSH-major] Bone Marrow Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Hodgkin Disease / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Bone Marrow / pathology. Bone Marrow / radionuclide imaging. Child. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18235420.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


77. Economopoulos T, Psyrri A, Dimopoulos MA, Kalogera-Fountzila A, Pavlidis N, Tsatalas C, Nikolaides C, Mellou S, Xiros N, Fountzilas G: CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group. Cancer J; 2007 Sep-Oct;13(5):327-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group.
  • BACKGROUND: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) improves outcomes in patients with previously untreated aggressive lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Epirubicin / adverse effects. Epirubicin / therapeutic use. Female. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Male. Middle Aged. Prednisone / adverse effects. Prednisone / therapeutic use. Rituximab. Vincristine / adverse effects. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17921732.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 3Z8479ZZ5X / Epirubicin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP protocol 1
  •  go-up   go-down


78. Pedrazzini E, Cerretini R, Noriega MF, Narbaitz M, Palacios MF, Negri P, Bengió R, Slavutsky I: Inversions of chromosomes 2 and 6 in mantle cell lymphoma. Cytogenetic, FISH, and molecular studies. Cancer Genet Cytogenet; 2006 Jun;167(2):164-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inversions of chromosomes 2 and 6 in mantle cell lymphoma. Cytogenetic, FISH, and molecular studies.
  • We here report the cytogenetic, fluorescence in situ hybridization (FISH), and molecular studies of 2 patients diagnosed with mantle cell lymphoma (MCL) that showed inversions of chromosomes 2 and 6 as part of complex karyotypes.
  • Considering that inversions are very infrequent events in MCL, our findings could be important for detecting genes potentially involved in development and/or progression of this aggressive non-Hodgkin lymphoma subtype.
  • [MeSH-major] Chromosome Inversion. Chromosomes, Human, Pair 2. Chromosomes, Human, Pair 6. Lymphoma, Mantle-Cell / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16737918.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


79. Lindén O, Hindorf C, Cavallin-Ståhl E, Wegener WA, Goldenberg DM, Horne H, Ohlsson T, Stenberg L, Strand SE, Tennvall J: Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res; 2005 Jul 15;11(14):5215-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
  • EXPERIMENTAL DESIGN: Cohorts of three to six patients with B-cell lymphoma received 185 MBq/m2 [90Y]epratuzumab with unconjugated epratuzumab (total protein dose 1.5 mg/kg) once weekly for two to four infusions, with [(111)In]epratuzumab coadministered at first infusion for scintigraphic imaging and dosimetry.
  • The overall objective response rate was 62% (95% confidence interval, 39-86%) in both indolent (75%) and aggressive disease (50%).
  • CONCLUSIONS: Radioimmunotherapy with weekly 185 MBq/m2 [90Y]epratuzumab achieved a high objective response rate (62%) across lymphoma subtypes, including durable CRs.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Antigens, CD / biosynthesis. Antigens, Differentiation, B-Lymphocyte / biosynthesis. Cell Adhesion Molecules / biosynthesis. Disease-Free Survival. Female. Gene Expression Profiling. Humans. Infusions, Intravenous. Lectins / biosynthesis. Male. Middle Aged. Radioimmunotherapy. Sialic Acid Binding Ig-like Lectin 2. Treatment Outcome. Yttrium Radioisotopes / therapeutic use

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033839.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / CD22 protein, human; 0 / Cell Adhesion Molecules; 0 / Lectins; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / Yttrium Radioisotopes; 0 / epratuzumab
  •  go-up   go-down


80. Deffenbacher KE, Iqbal J, Liu Z, Fu K, Chan WC: Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression. J Acquir Immune Defic Syndr; 2010 May 1;54(1):18-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIV-infected individuals have a significantly increased risk of developing an aggressive B-cell Non-Hodgkin Lymphoma relative to HIV(-) persons.
  • Due to their aggressive nature, AIDS-related lymphomas (ARL) can also be more difficult to classify.
  • Gene expression-based predictors robustly classified the B-ARL cases, distinguishing Burkitt lymphoma and diffuse large B-cell lymphoma, and identifying activated B-cell like and germinal center B-cell like molecular subtypes of diffuse large B-cell lymphoma.
  • [MeSH-major] Chromosome Aberrations. Gene Dosage. Gene Expression. HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / pathology
  • [MeSH-minor] Adult. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Comparative Genomic Hybridization. Diagnosis, Differential. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216076.001).
  • [ISSN] 1944-7884
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U01/CA114778; United States / NCI NIH HHS / CA / 5U01/CA114778-02S1; United States / NCRR NIH HHS / RR / P20 RR016469; United States / NCI NIH HHS / CA / U01/CA84967
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


81. Yamashita H, Izutsu K, Nakamura N, Shiraishi K, Chiba S, Kurokawa M, Tago M, Igaki H, Ohtomo K, Nakagawa K: Treatment results of chemoradiation therapy for localized aggressive lymphomas: A retrospective 20-year study. Ann Hematol; 2006 Aug;85(8):523-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of chemoradiation therapy for localized aggressive lymphomas: A retrospective 20-year study.
  • In this study we analyzed our cases of localized aggressive lymphoma treated in our institution during the last 20 years to compare the finding of this study with those of previous studies.
  • Forty patients with Ann Arbor stage I-II aggressive lymphoma were treated with 3-6 cycles of a CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisolone) and radiation therapy (30 or 40 Gy with involved field).
  • Combined chemotherapy and radiation therapy is safe, highly effective, and probably curative for most patients with stage I-II aggressive lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Prednisone / administration & dosage. Prognosis. Radiotherapy Dosage. Receptors, Interleukin-2 / blood. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16691398.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Receptors, Interleukin-2; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


82. Lin PC, Lee MY, Lin JT, Hsiao LT, Chen PM, Chiou TJ: Virus reactivation in high-risk non-Hodgkin's lymphoma patients after autologous CD34+ -selected peripheral blood progenitor cell transplantation. Int J Hematol; 2008 May;87(4):434-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Virus reactivation in high-risk non-Hodgkin's lymphoma patients after autologous CD34+ -selected peripheral blood progenitor cell transplantation.
  • From December 2001 to December 2004, ten high-risk aggressive non-Hodgkin's lymphoma (NHL) patients were enrolled in a program of high-dose chemotherapy plus autologous CD34+-selected PBPCs support.
  • [MeSH-major] Antigens, CD34 / metabolism. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / virology. Peripheral Blood Stem Cell Transplantation. Virus Activation
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Risk Factors. Transplantation, Autologous. Virus Diseases / complications. Virus Diseases / virology

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(10 ):827-34 [9404922.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2316-23 [17581918.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Br J Haematol. 2004 Aug;126(4):527-35 [15287946.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jan;12(1):84-94 [16399572.001]
  • [Cites] Br J Haematol. 1998 Feb;100(2):348-50 [9488625.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1018-26 [2474057.001]
  • [Cites] Bone Marrow Transplant. 1995 Mar;15(3):387-93 [7599563.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4029-35 [10590046.001]
  • [Cites] Bone Marrow Transplant. 1992 Sep;10(3):215-20 [1384898.001]
  • [Cites] N Engl J Med. 1997 May 1;336(18):1290-7 [9113932.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2324-30 [11895763.001]
  • [Cites] Blood. 1991 Apr 1;77(7):1587-92 [2009374.001]
  • [Cites] J Clin Oncol. 1990 Jan;8(1):84-93 [1688615.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2796-802 [9704732.001]
  • [Cites] Int J Hematol. 1999 Oct;70(3):193-9 [10561914.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3417-20 [7542169.001]
  • [Cites] J Hematother Stem Cell Res. 2000 Aug;9(4):557-64 [10982256.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2543-51 [7527453.001]
  • [Cites] Bone Marrow Transplant. 1996 May;17(5):691-7 [8733683.001]
  • [Cites] Eur J Haematol. 2006 Feb;76(2):102-8 [16405430.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(5):281-9 [12064366.001]
  • [Cites] Bone Marrow Transplant. 2005 Mar;35(5):479-87 [15654349.001]
  • [Cites] Int J Dev Biol. 2005;49(2-3):285-92 [15906243.001]
  • [Cites] Lancet. 1993 Jan 9;341(8837):85-6 [8093407.001]
  • [Cites] Int J Hematol. 2005 May;81(4):349-51 [15914368.001]
  • [Cites] Blood. 1997 May 15;89(10):3873-9 [9160696.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1131-7 [9060555.001]
  • (PMID = 18317882.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


83. Avilés A, Cleto S, Castañeda C, Nambo MJ: CMED in the treatment of nasal natural killer cell lymphoma with distant metastases. Hematology; 2007 Jun;12(3):241-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CMED in the treatment of nasal natural killer cell lymphoma with distant metastases.
  • INTRODUCTION: Nasal natural killer (NK) cell lymphoma that showed distant metastases generally showed an poor prognosis.
  • METHODS: Sixty-one patients fulfilled the criteria for NK cell lymphoma with distant metastases and all have very poor prognostic factors: high clinical risk, multiple extranodal presentation and bulky disease (tumor mass >10 cm).
  • CONCLUSIONS: Nasal NK cell lymphoma with distant metastases is considered an rare clinical entity, probably is under diagnosis because it has been included as stage III and IV in previous reports, that showed an very poor RFS and OS.
  • The treatment herein report could achieve good response and outcome, but it is evident that more specific and aggressive therapy is necessary in these setting of patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Killer Cells, Natural. Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Metastasis. Nose Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Etoposide / administration & dosage. Female. Humans. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Radiotherapy, Adjuvant. Salvage Therapy. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558700.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


84. Ardeshna KM, Kakouros N, Qian W, Powell MG, Saini N, D'Sa S, Mackinnon S, Hoskin PJ, Goldstone AH, Linch DC: Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol; 2005 Aug;130(3):363-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study aimed to determine the outcome of patients with relapsed or refractory lymphoma who have an inadequate response to first-line salvage therapy (1 degrees ST) and who subsequently receive a second-line salvage regimen (2 degrees ST) with the intention of ultimately proceeding to high-dose therapy.
  • The outcome of 57 patients [Hodgkin's Lymphoma 17, histologically-aggressive non-Hodgkin's Lymphoma (NHL) 26, histologically-indolent NHL 14] who received more than one modality of conventional-dose salvage therapy was analysed.
  • [MeSH-major] Lymphoma / therapy. Patient Selection. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Disease-Free Survival. Female. Hematopoietic Stem Cell Transplantation. Hodgkin Disease / mortality. Hodgkin Disease / therapy. Humans. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Recurrence. Remission Induction. Survival Rate. Transplantation, Autologous. Treatment Failure

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16042685.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


85. Ferreri AJ, Viale E, Guidoboni M, Resti AG, De Conciliis C, Politi L, Lettini AA, Sacchetti F, Dolcetti R, Doglioni C, Ponzoni M: Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. Ann Oncol; 2006 May;17(5):769-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa.
  • PATIENTS AND METHODS: The prevalence and clinical implications of HCV seropositivity were analyzed in 55 patients with ocular adnexa lymphoma (OAL) of MALT-type.
  • Concomitant HCV infection is associated with more disseminated disease and aggressive behavior in OAL, with a consequent potential negative impact in patients managed with radiotherapy alone.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2007 Feb;18(2):400-1; author reply 401-3 [17065589.001]
  • (PMID = 16524978.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


86. Cady FM, O'Neill BP, Law ME, Decker PA, Kurtz DM, Giannini C, Porter AB, Kurtin PJ, Johnston PB, Dogan A, Remstein ED: Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol; 2008 Oct 10;26(29):4814-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.
  • PURPOSE: Primary CNS lymphoma (PCNSL) is an aggressive lymphoma but clinically validated biologic markers that can predict natural history to tailor treatment according to risk are lacking.
  • Unlike systemic diffuse large B-cell lymphoma, del(6)(q22) is common and IGH translocations are infrequent and usually involve BCL6 rather than BCL2, suggesting a distinct pathogenesis.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2006 Aug;65(8):776-82 [16896311.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):737-41 [12591717.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):447-51 [12640061.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):487-93 [12657933.001]
  • [Cites] Virchows Arch. 2003 Aug;443(2):164-9 [12802586.001]
  • [Cites] Cerebrovasc Dis. 2004;17(2-3):224-7 [14707426.001]
  • [Cites] Cell. 2004 Jun 11;117(6):699-711 [15186772.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):159-66 [15215171.001]
  • [Cites] Blood. 1994 Apr 1;83(7):1757-9 [8142643.001]
  • [Cites] Blood. 1994 May 1;83(9):2423-7 [8167331.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Nov;7(11):833-46 [17057753.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1546-53 [17122510.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5711-5 [17116938.001]
  • [Cites] Blood. 1995 May 15;85(10):2877-84 [7742550.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):615-20 [9635710.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):123-33 [10337996.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1507-13 [15735126.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2233-9 [15800313.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3179-82 [16101124.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5718-27 [16009945.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2466-72 [16240449.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1281-8 [16525183.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2332-43 [17625604.001]
  • [Cites] Blood. 2008 Jan 1;111(1):292-301 [17720884.001]
  • [Cites] Leukemia. 2008 Feb;22(2):400-5 [17989719.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1268-72 [17989713.001]
  • [Cites] Nat Rev Immunol. 2005 Jan;5(1):43-57 [15630428.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1445-51 [10550299.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1386-92 [10555007.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):261-6 [10659013.001]
  • [Cites] Brain Pathol. 2000 Jan;10(1):73-84 [10668897.001]
  • [Cites] Neurosurgery. 2000 Aug;47(2):454-6; discussion 456-7 [10942021.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Mar;125(2):147-50 [11369058.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Br J Haematol. 2002 May;117(2):322-32 [11972514.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Oct;61(10):926-33 [12387458.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):323-31 [12559880.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1383-97 [8055462.001]
  • (PMID = 18645192.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA15083; United States / NCI NIH HHS / CA / P50 CA108961
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins
  • [Other-IDs] NLM/ PMC2653136
  •  go-up   go-down


87. Fridrik MA, Hausmaninger H, Lang A, Drach J, Krieger O, Geissler D, Michlmayr G, Ulsperger E, Chott A, Oberaigner W, Greil R: Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma. Ann Hematol; 2010 Mar;89(3):273-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.
  • This study aimed to determine whether dose-dense therapy improves 3-year survival over the standard therapy for untreated aggressive lymphoma.
  • One hundred and fifteen patients with untreated aggressive lymphoma were stratified by center, age, and international prognostic index and randomized to one of two treatment arms.
  • Dose-dense therapy with CEOP/IMVP-Dexa is feasible and resulted in an absolute increase of 34% in the survival probability compared to CHOP in untreated patients with aggressive lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide. Dexamethasone. Doxorubicin. Epirubicin. Etoposide. Female. Filgrastim. Granulocyte Colony-Stimulating Factor. Humans. Ifosfamide. Infection / chemically induced. Male. Methotrexate. Middle Aged. Prednisolone. Prognosis. Recombinant Proteins. Survival Rate. Vincristine. Young Adult

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19693500.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00517894
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; PVI5M0M1GW / Filgrastim; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


88. Karantanis D, Subramaniam RM, Peller PJ, Lowe VJ, Durski JM, Collins DA, Georgiou E, Ansell SM, Wiseman GA: The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clin Lymphoma Myeloma; 2008 Apr;8(2):94-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma.
  • PURPOSE: To our knowledge, there are no published data pertinent to the use of [(18F)]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in patients with natural killer (NK)/T-cell lymphoma.
  • The purpose of this study was to assess the value of FDG PET/CT in this aggressive type of non-Hodgkin lymphoma.
  • PATIENTS AND METHODS: All patients with NK/T-cell lymphoma referred for FDG PET/CT at our institution from July 2001 to July 2006 were retrospectively studied.
  • RESULTS: Twenty-one PET/CT examinations were performed in 10 patients with NK/T-cell lymphoma.
  • CONCLUSION: Viable NK/T-cell lymphoma is intensely FDG hypermetabolic.
  • [MeSH-major] Fluorodeoxyglucose F18. Killer Cells, Natural / radionuclide imaging. Lymphoma, T-Cell / radionuclide imaging
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Positron-Emission Tomography / methods. Radioisotopes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501102.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


89. Mohammadianpanah M, Omidvai S, Mosalei A, Ahmadloo N: Treatment results of tonsillar lymphoma: a 10-year experience. Ann Hematol; 2005 Apr;84(4):223-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of tonsillar lymphoma: a 10-year experience.
  • Primary extranodal non-Hodgkin's lymphomas of the head and neck account for 10-20% of all non-Hodgkin's lymphomas.
  • Primary tonsillar lymphoma accounts for less than 1% of head and neck malignancies, although the tonsil is the most common primary extranodal site of head and neck non-Hodgkin's lymphomas.
  • In this study we analyzed our cases of tonsillar lymphoma treated in our institution during the last 10 years to compare the finding of this study with those of previous studies.
  • We reviewed the cases of tonsillar lymphoma treated in the Radiation Oncology Department of Shiraz University from 1992 to 2002.
  • The vast majority of patients presented in early stages with aggressive histology.
  • A late fatal side effect was observed in one patient who developed radiation-induced sarcoma 7 years after initial diagnosis and died 8 months later without evidence of recurrent lymphoma.
  • Combined chemotherapy and radiation therapy is safe, highly effective, and probably curative for most patients with primary tonsillar lymphoma.
  • [MeSH-major] Combined Modality Therapy / methods. Lymphoma, Non-Hodgkin / therapy. Tonsillar Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Disease-Free Survival. Follow-Up Studies. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant / adverse effects. Remission Induction / methods. Retrospective Studies. Risk Factors. Survival Rate. Tonsillectomy. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15042316.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


90. Kuper-Hommel MJ, Snijder S, Jansen-Heijnen ML, Vreugdenhil A, Noordijk EM, Kluin-Nelemans HC, Coebergh JW, van Krieken JH: Treatment and survival of patients with thyroid lymphoma: a population-based study with clinical and pathologic reviews. Clin Lymphoma Myeloma; 2005 Nov;6(3):240-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and survival of patients with thyroid lymphoma: a population-based study with clinical and pathologic reviews.
  • PATIENTS AND METHODS: A retrospective population-based survey of 38 patients with thyroid lymphoma was taken.
  • The most common subtype was diffuse large B-cell lymphoma (DLBCL; 63%) followed by extranodal marginal zone lymphoma (ENMZL; 29%).
  • Ten of the patients with DLBCL showed a concomitant low-grade mucosa-associated lymphatic tissue component, and 4 cases of aggressive ENMZL were diagnosed.
  • Two-year overall survival rate was 59% for all patients, 68% for patients with localized disease, and 47% for patients with disseminated lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy. Thyroid Neoplasms / pathology. Thyroid Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354330.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Altamirano J, Esparza JR, de la Garza Salazar J, Calvo PS, Vera SR, Chalapud Revelo JR, Estrada G: Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET. Arch Med Res; 2008 Jan;39(1):69-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We undertook this study to determine the diagnostic accuracy of (18)FDG after three cycles and at the end of chemotherapy in non-Hodgkin's lymphoma (NHL) or Hodgkin's lymphoma (HL).
  • We also evaluated the role of (67)Ga, bone marrow aspiration (BMA), and computed tomography (CT) in monitoring lymphoma treatment.
  • PET after three cycles of chemotherapy is predictive of 18-month outcome in patients with intermediate and aggressive NHL and HL and may help in the identification of patients who would benefit from more intensive treatment or from a change in chemotherapy.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067998.001).
  • [ISSN] 0188-4409
  • [Journal-full-title] Archives of medical research
  • [ISO-abbreviation] Arch. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


92. Queiroga EM, Gualco G, Chioato L, Harrington WJ, Araujo I, Weiss LM, Bacchi CE: Viral studies in burkitt lymphoma: association with Epstein-Barr virus but not HHV-8. Am J Clin Pathol; 2008 Aug;130(2):186-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viral studies in burkitt lymphoma: association with Epstein-Barr virus but not HHV-8.
  • Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin lymphoma, composed of a monomorphic population of medium-sized B cells with a high proliferation rate and a consistent MYC translocation.
  • Kaposi sarcoma-associated herpesvirus, or human herpesvirus 8 (HHV-8), infects a wide range of normal cells, having a well-established role in the pathogenesis of various neoplasms, including Kaposi sarcoma, primary effusion lymphoma, multicentric Castleman disease (MCD) and MCD-associated plasmablastic lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2005 Aug;19(8):1391-8 [15973450.001]
  • [Cites] J Exp Med. 2005 Aug 15;202(4):479-84 [16103407.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):834-7 [16136049.001]
  • [Cites] J Clin Pathol. 2005 Oct;58(10):1039-45 [16189148.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):123-7 [16330952.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):23-31 [16360412.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):735-42 [16498502.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Acta Haematol. 2007;117(3):129-31 [17135725.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):13-24 [17991301.001]
  • [Cites] Haematologica. 2005 Nov;90 Suppl:ECR35 [16266926.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1269-70 [10534180.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2130-6 [11264181.001]
  • [Cites] Clin Infect Dis. 2002 Feb 15;34(4):559-60 [11797191.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):471-7 [12580962.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Acta Otolaryngol. 2004 Apr;124(3):318-23 [15141762.001]
  • [Cites] J Gen Virol. 1987 Nov;68 ( Pt 11):2853-62 [2824665.001]
  • [Cites] Blood. 1992 Jun 15;79(12):3261-6 [1317726.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1396-403 [7858270.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):17-23 [8546204.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Mod Pathol. 1996 Jan;9(1):63-7 [8821959.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] Histol Histopathol. 1997 Jul;12(3):595-601 [9225139.001]
  • [Cites] Arch Dermatol. 1998 Jun;134(6):751 [9645650.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] J Cutan Pathol. 2005 Jan;32(1):21-7 [15660651.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):626-8 [15917415.001]
  • (PMID = 18628086.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112217-03; United States / NCI NIH HHS / CA / R01 CA112217; United States / NCI NIH HHS / CA / CA121935-03; United States / NCI NIH HHS / CA / 5R01CA082274; United States / NCI NIH HHS / CA / R01 CA112217-03; United States / NCI NIH HHS / CA / R01 CA082274-08; United States / NCI NIH HHS / CA / CA082274-08; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / R01 CA121935-03; United States / NCI NIH HHS / CA / U01 CA121947-016821; United States / NCI NIH HHS / CA / 5R01CA112217; United States / NCI NIH HHS / CA / R01 CA121935; United States / NCI NIH HHS / CA / CA121947-016821
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS125501; NLM/ PMC2718775
  •  go-up   go-down


93. Trcić RL, Sustercić D, Kuspilić M, Jelić-Puskarić B, Fabijanić I, Kardum-Skelin I: Recurrent chromosomal abnormalities in lymphomas in fine needle aspirates of lymph node. Coll Antropol; 2010 Jun;34(2):387-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The detection of specific chromosomal abnormalities is important in the diagnostic workup of aggressive lymphomas, giving its impact on the treatment strategies and prognosis.
  • This has been accomplished by using the fluorescent in situ hybridisation method (FISH) performed on fine needle aspiration (FNA) specimens what is attractive in the diagnosis of lymphoma in the comparation with other methods for collecting samples.
  • The cytogenetic analyses were performed in series of 80 patients with lymphoma (43 women and 37 men, median age 48, range 3-90 years).
  • In our series 89.0% (71) of the specimens yield sufficient numbers of analysable metaphases, comprising 63 non-Hodgkin lymphomas (NHL) and 8 examples of Hodgkin disease (HD).
  • Four abnormal clones detected in Hodgkin disease were typically consisted of a small percentage of metaphases.
  • [MeSH-major] Chromosome Aberrations / classification. Lymph Nodes / pathology. Lymphoma / genetics. Lymphoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle / methods. Biopsy, Needle / methods. Female. Gene Rearrangement / genetics. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell / pathology. Male. Middle Aged. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698107.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


94. Osterborg A, Steegmann JL, Hellmann A, Couban S, Mayer J, Eid JE: Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy. Br J Haematol; 2007 Mar;136(5):736-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy.
  • Anaemia is a common complication in the treatment of patients with aggressive non-Hodgkin lymphoma (NHL), but there are no published data on the effect of erythropoiesis-stimulating agents in such patients.
  • Ninety-three anaemic patients with aggressive NHL who were receiving chemotherapy (including many advanced NHL, heavily pretreated patients) were randomised to receive 2.1, 4.2 or 6.3 microg/kg C.E.R.A. subcutaneously once every 3 weeks for 12 weeks.
  • During weeks 5-13, the mean haemoglobin changes from baseline in the intent-to-treat population were increases of 0.2, 2.4, and 5.7 g/l in the 2.1, 4.2, and 6.3 microg/kg treatment groups, respectively, and 4.4, 5.7 and 6.8 g/l in the per-protocol population at the respective dose levels. C.E.R.A. was generally well tolerated in all three groups. C.E.R.A. appeared to have dose-dependent clinical activity in most anaemic patients with aggressive NHL who were receiving chemotherapy.
  • [MeSH-major] Anemia / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Erythropoietin / administration & dosage. Lymphoma, B-Cell / drug therapy. Polyethylene Glycols / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Recombinant Proteins. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313376.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / continuous erythropoietin receptor activator; 11096-26-7 / Erythropoietin; 30IQX730WE / Polyethylene Glycols
  •  go-up   go-down


95. García Ortiz LM, Jaume Anselmi F, Ramírez Rivera J, Casiano Quiles W, Márquez Santiago R: Non-Hodgkin's lymphoma presenting as ulcerative colitis. Bol Asoc Med P R; 2006 Apr-Jun;98(2):140-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma presenting as ulcerative colitis.
  • High-grade Non-Hodgkin's lymphomas are very aggressive type of malignancies.
  • We report a high grade small B-cell (Burkitt's like) Non-Hodgkin's lymphoma that initially was considered and treated as ulcerative colitis without improvement or resolution of symptoms for nine months.
  • [MeSH-major] Colitis, Ulcerative / etiology. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19606804.001).
  • [ISSN] 0004-4849
  • [Journal-full-title] Boletín de la Asociación Médica de Puerto Rico
  • [ISO-abbreviation] Bol Asoc Med P R
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


96. Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, Larson SM, Yeung HW: Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol; 2005 Jul 20;23(21):4643-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.
  • PURPOSE: (18)Fluorodeoxyglucose positron emission tomography (FDG PET) is widely used for the staging of lymphoma.
  • We investigated whether the intensity of tumor FDG uptake could differentiate between indolent and aggressive disease.
  • MATERIALS AND METHODS: PET studies of 97 patients with non-Hodgkin's lymphoma who were untreated or had relapsed and/or persistent disease and had not received treatment within the last 6 months were analyzed, and the highest standardized uptake value (SUV) per study was recorded.
  • RESULTS: FDG uptake was lower in indolent than in aggressive lymphoma for patients with new (SUV, 7.0 +/- 3.1 v 19.6 +/- 9.3; P < .01) and relapsed (SUV, 6.3 +/- 2.7 v 18.1 +/- 10.9; P = .04) disease.
  • Despite overlap between indolent and aggressive disease in the low SUV range (indolent, 2.3 to 13.0; aggressive, 3.2 to 43.0), all cases of indolent lymphoma had an SUV <or= 13.
  • A receiver operating characteristic (ROC) analysis demonstrated that the SUV distinguished reasonably well between aggressive and indolent disease (area under ROC curve, 84.7%), and an SUV > 10 excluded indolent lymphoma with a specificity of 81%.
  • CONCLUSION: FDG uptake is lower in indolent than in aggressive lymphoma.
  • Patients with NHL and SUV > 10 have a high likelihood for aggressive disease.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Radiopharmaceuticals / pharmacokinetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Jul 20;23(21):4577-80 [15837974.001]
  • (PMID = 15837966.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


97. van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE, Peters WG, Coebergh JW: Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer; 2005 May;41(7):1051-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry.
  • The prevalence of co-morbidity among elderly lymphoma patients is associated with a decrease in the use of chemotherapy.
  • This study assessed the independent prognostic effect of co-morbidity in 1551 unselected lymphoma patients, diagnosed between 1995 and 2001 in the area of the population-based Eindhoven Cancer Registry.
  • The prevalence of serious co-morbidity was 58% for patients with Hodgkin's disease (HD) who were over 60 years of age and 66% for patients with non-Hodgkin's lymphoma (NHL) who were over 60 years of age.
  • The administration of chemotherapy declined in the presence of co-morbidity for elderly patients with early-stage HD and elderly patients with aggressive NHL.
  • [MeSH-major] Hodgkin Disease / mortality. Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Comorbidity. Female. Follow-Up Studies. Humans. Male. Middle Aged. Netherlands / epidemiology. Prevalence. Prognosis. Proportional Hazards Models. Registries. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15862755.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


98. Aggarwal C, Gupta S, Vaughan WP, Saylors GB, Salzman DE, Katz RO, Nance AG, Tilden AB, Carabasi MH: Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant; 2006 Jul;12(7):770-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
  • Forty-nine patients with intermediate- and high-risk aggressive non-Hodgkin lymphoma underwent autologous hematopoietic stem cell transplantation (autoHSCT) using the regimen of busulfan (Bu), cyclophosphamide (Cy), and etoposide (E) that was originally developed for allogeneic HSCT.
  • After substitution of PKD IV Bu in the BuCyE regimen, we observed lower nonrelapse mortality with increased overall and progression-free survivals in patients with intermediate- and high-risk aggressive non-Hodgkin lymphoma who underwent autoHSCT.
  • [MeSH-major] Busulfan / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / therapy. Myeloablative Agonists / administration & dosage. Transplantation Conditioning / methods
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Chi-Square Distribution. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Secondary Prevention. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785066.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloablative Agonists; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  •  go-up   go-down


99. Zuo XL, Zhou X, Meng J, Zhang KJ, Liu XH, Yang HQ: [A study on the expression of myeloid cell leukemia 1 proteins and survivin and their relation with B cell apoptosis in non-Hodgkin's lymphoma]. Zhonghua Nei Ke Za Zhi; 2006 Feb;45(2):133-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A study on the expression of myeloid cell leukemia 1 proteins and survivin and their relation with B cell apoptosis in non-Hodgkin's lymphoma].
  • OBJECTIVE: To explore the expression of myeloid cell leukemia 1 (MCL-1) proteins and survivin and its correlation with cell apoptosis as well as with the development and progression of B cell non-Hodgkin's lymphoma (B-NHL).
  • The expression of MCL-1 proteins in aggressive B-NHL was higher than that in indolent B-NHL (70.0 % vs 30.8 %, P < 0.05).
  • The expression of survivin in aggressive B-NHL was also higher than that in indolent B-NHL (80.0% vs 46.2%, P < 0.05).
  • [MeSH-major] Apoptosis. B-Lymphocytes / pathology. Lymphoma, Non-Hodgkin / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Inhibitor of Apoptosis Proteins. Lymphoid Tissue / metabolism. Lymphoid Tissue / pathology. Male. Middle Aged. Myeloid Cell Leukemia Sequence 1 Protein

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16624124.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


100. Cillessen SA, Meijer CJ, Notoya M, Ossenkoppele GJ, Oudejans JJ: Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles. J Pathol; 2010 Apr;220(5):509-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common type of adult non-Hodgkin lymphoma and is treated with chemotherapy in combination with rituximab.
  • Despite this aggressive therapy, the disease is fatal in 30-40% of patients.
  • In order to survive, lymphoma cells depend on disruption of the apoptosis pathway by mutations in apoptosis inducing genes or by continuous expression of anti-apoptotic proteins.
  • The development of molecules targeting these apoptosis inhibitors provides a very promising opportunity to specifically target tumour cells without toxicity to non-malignant cells in DLBCL patients.
  • [MeSH-major] Apoptosis / physiology. Apoptosis Regulatory Proteins / antagonists & inhibitors. Lymphoma, Large B-Cell, Diffuse / therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087881.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Neoplasm Proteins
  • [Number-of-references] 119
  •  go-up   go-down






Advertisement